BG62729B1 - DERIVATIVES OF 1 (2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC DERIVATIVES OF 1 (2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACIDS AS SENSIBILIZERS OF MULTIMEDlCAMENTOUSRESISTANT CANCER CELLS - Google Patents

Abstract

The invention relates to compounds having the formula which preserve, increase or restore the sensitivity of the cells to therapeutical or prophylactic agents. The invention also relates to pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions are applied in the treatment of multimedicamentousresistant cells for the prevention of the development of the resistance and in cancer therapy in the presence of multimedicamentousresistant cells. 18 claims

Description

TECHNICAL FIELD

The present invention relates to novel compounds that retain, enhance or restore the sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of this invention are particularly suitable for treating multidrug-resistant cells, preventing the development of multidrug-resistant, and for use in multidrug-resistant cancer therapy.

BACKGROUND OF THE INVENTION

One major problem affecting the efficacy of chemotherapy is the evolution of cells that, under the influence of a chemotherapy drug, become resistant to many structurally different drugs and therapeutic agents. The manifestation of such multidrug resistance often occurs in the presence of overexpression of 170-kDA membrane Rg glycoprotein (gp-170). The gp-170 protein is present except in cancer cells and in the plasma membranes of some healthy tissues and is homologous to bacterial transport proteins (Hait et al., Cancer Communications, Vol. 1 (1), 35 (1989); West, TIBS. Vol. 15, 42 (1990). Protein acts as a pumping pump, creating drug resistance by actively extracting toxic chemicals. Although the mechanism of action of the pump is unknown, the gp-170 protein is thought to function by ejecting substances that have some common chemical or physical characteristics, such as hydrophobicity, the presence of carboxyl groups, or the presence of neat glutathione (see West).

Various chemical agents have been applied in order to suppress multidrug resistance and restore drug sensitivity. Although some drugs have improved the response of MDR cells to chemotherapeutic agents, they have often been accompanied by undesirable clinical side effects (see Hait et al.). For example, although the widely accepted immunosuppressant cyclosporin A (CsA) may sensitize some cancer cells to chemotherapeutic agents (Slater et al., Br. J. Cancer, Vol. 54, 235 (1986)), required to achieve this effect concentration produces significant immunosuppression in patients whose immune system has already been compromised by chemotherapy (see Hait et al.). Similarly, calcium transport blockers as well as calmodulin inhibitors sensitize multidrug-resistant (MDR) cells but also lead to undesirable physiological effects (see Hait et al.; Twentyman et al., Br. J. Cancer, Vol. 56, 55 (1987).

Compounds (patents WO 92/00278, WO 92/19593) are known for the treatment of autoimmune diseases, which are used to prevent or significantly reduce rejection in bone marrow or organ transplants.

Tetrahydropyran compounds (patent GB 2, 247, 456) are known for use in organ transplant rejection and other autoimmune diseases.

Recent developments have led to agents that are said to have potentially greater clinical relevance for the sensitization of MDR cells. These agents include CsA analogs that do not have an immunosuppressive effect, such as 11-methyl-leucine cyclosporin (11-methyl-leu CsA) (see Halt et ai .; Twentyman et al.) Or agents that are effective at low doses, such as immunosuppressant FK-506 (Epand and Epand, Anti-Cancer Drug Design 6, 189 (1991)). Despite this development, there is still a need for effective agents that can be used to sensitize MDR cells to therapeutic or prophylactic agents or to prevent the development of multidrug resistance.

SUMMARY OF THE INVENTION The present invention relates to novel compounds that are useful for maintaining, enhancing, or restoring drug sensitivity of multidrug-resistant ("MDR") cells, to compositions containing these compounds, and to methods for their use. The compounds of this invention can be used alone or in combination with other therapeutic or prophylactic agents to preserve, enhance or restore the therapeutic or prophylactic effects of drugs in cells and especially in MDR cells, or prevent the formation of MDR cells. According to one of the ingredients of this invention, these novel compounds, compositions and methods have been successfully used to support or enhance the effectiveness of chemotherapeutic approaches to the treatment or prevention of cancer and other diseases.

The present invention also provides methods for preparing the compounds of this invention as well as intermediates useful for these methods.

The invention relates to compounds of general formula (1)

where A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl);

wherein B and D are independently of one another and denote hydrogen, Ar, straight or branched (C 1 -C 10) -alkyl or straight or branched (C 2 -C 10) -alkenyl or alkynyl groups; substituted by (C5-C7) -cycloalkyl groups: (C1-C6) straight- or branched-chain alkyl groups, (C2-C6) -alkenyl or straight- or branched-chain alkynyl groups; substituted by (C5-C7) cycloalkenyl groups: (C1-C6) straight or branched chain alkyl groups, (C2-C6) straight or branched chain alkynyl or alkynyl groups; or straight or branched (C 1 -C 6) -alkyl or straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; however, in any case, any of the CH ₂ groups of said alkyl, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of 0, S, SO, SO ₂ , N and NR, where R is selected from the group consisting of hydrogen, a (C 1 -C 4) straight or branched chain alkyl group, a (C 2 -C 4) alkenyl or straight or branched chain alkynyl group, and a (C 1 -C 4) bridged alkyl group, wherein the bridge is formed between the nitrogen and carbon atoms of said heteroatom-containing chain so as to form a ring; the ring in question may be fused to an Ar group; or:

wherein Q is hydrogen, straight or branched (C 1 -C 6) -alkyl, or straight or branched (C 2 -C 6) -alkenyl or alkynyl groups;

wherein T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of ox, H, hydroxyl, O- (C 1 -C 4) -alkyl or O- (C2-C4) -alkenyl groups;

wherein Ar is a carbocyclic aromatic moiety selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl. anthracenyl as well as mono- and bicyclic heterocyclic ring systems with 5- or 6-membered individual rings which may contain in one or two rings a total of 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur. Such ring systems include heterocyclic aromatic rings selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl _2- pyrrolyl, oxazolyl, thiazolyl, imidazolol, imidazolol, imidazolol -pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4thiastiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithanyl , indolizinyl, indolylo, isoindolyl, 3H-indolyl, indolinyl, benzo [b] furanyl, benzo [b] thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quin olinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazaolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl;

wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6) straight or branched chain alkyl groups, (C 2 -C6) straight or branched chain alkenyl groups, O- (C1-C4) straight or branched chain alkyl groups, O- (C2-C4) straight or branched chain alkenyl groups, O-benzyl, O- phenyl, 1,2-methylenedioxy, amino, carboxyl, straight- or branched-chain straight or branched N- (C 1 -C 5 -alkyl or alkenyl) -carboxamides, Ν, Ν or - (C 1 -C 5 -alkyl with straight or branched) Onnen alkyl or C2-C5 alkenyl straight or branched alkenyl) carboxamides, N-morpholinocarboxamide, Νbenzilkarboksamid, N-thiomorpholinocarboxamide, N-picolinoyl * carboxamide, 0-X, CH ₂ - (CH _{2) q} - X, O- (CH ₂ ) _q -X, (CIS-O-X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2thienyl, 3-thienyl and pyrimidyl, with q being 0-2;

where L is hydrogen or U; M is hydrogen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U;

wherein U is hydrogen, straight- or branched-chain O- (C 1 -C 4) -alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups; Straight or branched (C2-C6) alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y;

wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-pyrrolinyl, 3pyrrolinyl, pyrrolidinyl, 1,3-dioxolyl, 2-imidazolinyl, imidazolidinyl,

2H-pyranyl, 4H-pyranyl, piperidyl, 1,4-dioxanyl, morpholinyl, 1,4dithianyl, thiomorpholinyl, piperazinyl, quinuclidinyl and heterocyclic aromatic groups as defined above;

wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups (C1-C6) straight- or branched-chain alkenyl groups; straight- or branched-chain O- (C 1 -C 4) alkyl groups; O- (C2-C4) straight or branched chain alkenyl groups, O-benzyl, O-phenyl, 1,2methylenedioxy, amino and carboxyl;

wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or wherein J and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO ₂ ;

where m is 0-3.

Stereochemistry at positions 1 and 2 (Formula I) can be independently R or S.

Preferably at least one of B or D is independently a straight chain terminating with an aryl group, i.e. a group represented by the formula - (CH ₂ ) ₁ - (X) - (CH ₂ ) ₅ - Ar, where r is 0-4;

s is 0-1;

Ar is defined as above and each X is independently selected from the group consisting of CH ₂ , O, S, SO, SO ₂ , N and NR, where R is selected from the group consisting of hydrogen, (C1 -C4) straight- or branched-chain alkyl groups, (C2-C4) -alkenyl or straight- or branched-chain alkynyl groups, and (C1-C4) bridge alkyl, forming a bridge between the nitrogen atom and the Ar-group.

According to one of the ingredients of the invention, the heterocyclic aromatic groups are selected from the group comprising furan, thiophene, pyrrole, pyridine, indolizine, indole, isoindole, benzo [b] furan, benzo [b] thiophene, 4Hquinolysin, quinoline, isoquinoline, 1. 2,3,4-tetrahydro-quinoline, isoxazole and

1,2,3,4-tetrahydroisoquinoline.

According to another ingredient of this invention, at least one of B or D is selected from the group consisting of a (C2-C10) straight or branched-chain alkynyl group substituted with a (C5-C7) -cycloalkyl radical (C2-C6) alkynyl group with a straight or branched chain substituted by a (C5-C7) cycloalkenyl moiety (C2-C6) -alkynyl group with a straight or branched chain and an Ar-substituted (C2-C6) -alkynyl group with a straight or branched chain.

Also within the scope of the invention are compounds of formula (I) wherein at least one of B or D is selected from the group consisting of Ar ', Ar'-substituted (C 2 -C 6) -alkyl groups with a straight or branched chain, and Straight or branched chain (C 2 -C 6) -alkenyl or alkynyl groups; wherein Ar 'is an Ar-group substituted by one to three substituents independently selected from the group consisting of N- (C 1 -C 5 -alkyl or C 2 -C 5 -alkenyl of straight or branched chain) -carboxamides, Ν , Ν-di- (C1-C5 alkyl or C2-C5 alkenyl leeks or branched alkenyl) carboxamides, N-morpholinocarboxamide, N-benzyl carboxamide, Ntiomorfolinokarboksamid, N-picolinoylcarboxamide, O-X, CH ₂ - (CH ₂ ) _q - X, O - CH ₂ - (CH ₂ ) _q - X, (CH ₂ ) _q - 0 - X and CH = CH-X; where X is 4-methoxyphenyl,

2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazoyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, wherein q is 0-2.

Examples of some preferred compounds of formula (I), wherein J and K together form a 5-7 membered heterocyclic ring are shown in Table 1 and are further illustrated by the embodiments of the invention.

It will be appreciated that with respect to aspects of the invention related to the use of the compounds described in compositions or methods of treatment or prophylaxis of multidrug resistance, these compounds are represented by formula (I) as defined above. With respect to aspects of the present invention related to the novel compounds described herein, these compounds are represented by the formula (I) defined above, but with the exception that B and D cannot be hydrogen.

Table 1

Comp. η m in D Ah 2 1 0 3- (Pyridin-2-yl) - wasted 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 3 2 0 3-Phenylpropyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 4 2 0 3-Phenoxyphenyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 5 2 0 Phenyl 3-Phenoxyphenyl 3,4,5-T rimethoxyphenyl 6 2 0 Phenyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 7 2 0 2- (Pyridin-2-yl) - ethyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 8 2 0 E-3- [trans- (4- 3-Phenylpropyl 3,4,5-T rimethoxyphenyl

hydroxycyclohexyl)] - 2-methyl · eth-2-enyl

Syed. η m C. D Ah 9 2 0- (Pyridin-3-yl) - wasted 3-Phenyl propyl 3,4,5-T rimethoxyphenyl 10 2 0 Benzyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 11 2 0 Benzyl 3- (3-indolyl) - wasted 3,4,5-T rimethoxyphenyl 12 2 O 2-Phenylethyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 13 2 0 2- (4-Methoxy- phenyl) ethyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 14 2 0 2- (4-Methoxy- phenyl) ethyl 3-Phenylpropyl Phenyl 15 2 0 3- (N-benzimidazolyl) propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 16 2 1 Benzyl 2-Oenylethyl 3,4,5-T rimethoxyphenyl 17 2 0 3- (4-Methoxy- phenyl) propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 18 2 0- (Pyridin-3-yl) - wasted 3-Phenylpropyl Phenyl 19 2 0 3- (Pyridin-2-yl) - wasted 3-Phenylpropyl Phenyl 20 2 0 3- (Pyridin-2-yl) - wasted 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 21 2 0 3- (Pyridin-2-yl) - wasted 3-Phenylpropyl tert-Butyl 22 2 0 3- (Pyridin-2-yl) - propyl N-oxide 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 23 2 0 3- [bc7-azaino- lyl) -propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 24 2 0- (Pyridin-3-yl) - wasted 3- (4-Methoxy- phenyl) propyl 3,4,5-T rimethoxyphenyl

Comp. η m in D Ah 25 2 0 3- (M-purinyl) - wasted 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 26 2 0 3- (4-Hydroxy- til phenyl) propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 27 2 0 3- (Pyridin-3-yl) - wasted 3-Phenylpropyl 3-Benzyloxyphenyl 28 2 0 3- (Pyridin-3-yl) - wasted 3-Phenylpropyl 3-allyloxyphenyl 29 2 0 3- (Pyridin-3-yl) - wasted 3-Phenylpropyl 3-Isopropoxyphenyl 30 2 0 3- (T -ophen-2-yl) - wasted 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 31 2 0 3- (4-Carboxy- phenyl) propyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 32 2 0 3-Phenylbutyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 33 2 0 2-Hydroxime ethyl phenyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 34 2 0 2-Allyl-oxy- phenyl 3-phenylpropyl 3,4,5-Trimethoxyphenyl 35 2 0 3- (3-Hydroxymethylphenyl) propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 36 2 0 3- (3-Carboxy- phenyl) propyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 37 2 0 C-Hydroxy- tilphenyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 38 2 0 2-Hydroxy- phenyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 39 2 0 Pyridin-3-yl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 40 2 0 3- (Thiophen-2-yl) - 4-Phenylbutyl 3,4,5-Trimethoxyphenyl

wasted

Syed. η m in D Ah 41 2 0 5-Phenylpentyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 42 2 0 C-Allyloxy- wasted 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 43 2 0 3-f4- (N, N-AMMethylaminocarbonyl) -phenyl] propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 44 2 0 3- [4- (morpholine- 4-carbonyl) phenyl] -propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 45 2 0 4-Allyloxybutyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 46 2 0 C-Allyloxyprop- 1-ynyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 47 2 0 3- [4- (piperidine- 1-carbonyl) phenyl] -propyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 48 2 0 5-Allyloxy- nonyl 3-Phenylpropyl 3.4,5-Trimethoxyphenyl 49 2 0 Methyl 3,5-Bis (benzyl- oxy) phenyl 3,4,5-T rimethoxyphenyl 50 2 0 2-Allyloxyethyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 51 2 0 C-Allyloxy- (E) - prop-1-enyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 52 2 0 3- [3- (morpholine- 4-carbonyl) phenyl] -propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 53 2 0 Dec-9-enyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 54 2 0 3- [4- (N-benzylamincarbonyl) - phenyl] -propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl

Syed. η m in D Ah 55 2 0 3- [4- (Thiomorpholine-4-carbonyl) phenyl] -propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 56 2 0 3- (morpholine-4carbonyl) phenyl-propyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 57 2 0 3- [4- (1-methylpiperazine-4carbonyl) phenyl] propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 58 2 0 3- [4- (1-Benzylpiperazine-4carbonyl) phenyl] propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 59 2 0 3- [3- (N-benzylaminocarbonyl) phenyl] propyl 3-Phenylpropyl 3,4,5-Trimethoxyphenyl 60 2 0 3- [4- (M-pyridine- 2-ylaminecarbonyl) -phenyl] propyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 61 2 0 Pyridin-3-yl 3- (Pyridine-3- yl) -propyl 3,4,5-T rimethoxyphenyl 62 2 0 Prop-2-enyl 3,4-Bis- (pyri- din-4-ylmethole- si) phenyl 3,4,5-T rimethoxyphenyl 63 2 0 Pyridin-3-yl 3- (Pyridine-4- 3,4,5-T rimethoxyphenyl

ilmethoxy) phenyl

η m in D Ah 2 0 3-Phenylpropyl 3- (Pyridin-4-yl methoxy) phenyl 3,4,5-Trimethoxyphenyl 2 0 3-Phenylpropyl 3,4-Bis- (pyridin-4-ylmethoxy) phenyl 3,4,5-Trimethoxyphenyl 2 0 Methyl 3,4-Bis- (pyridin-4-ylmethoxy) phenyl 3,4,5-Trimethoxyphenyl 2 0 3-Phenylpropyl 2,3,4-Tris- (pi- ridin-4-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 2 0 3-Phenylpropyl 3- (morpholine-4- carbonyl) -4- (pyridin-4-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 2 0 Methyl 3-Phenylpropyl 3,4,5-Tris- (pi- ridin-4-ylmethoxy) phenyl 3,4,5-Tris- (pi- ridin-4-ylmethoxy) phenyl 3.4.5- T rimethoxyphenyl 3.4.5- Trimethoxyphenyl 2 0 Methyl 3,5-Bis- (pyridin-4-ylmethoxy) phenyl 3,4,5-Trimethoxyphenyl 2 0 3,5-Bis- (pyri- din-4-ylmethole- si) phenyl Methyl 3,4,5-Trimethoxyphenyl

Comp. η m in D At 73 2 0 Methyl 3,5-Bis- (pyridin-4-ylmethoxy) -4-methylphenyl 3,4,5-T rimethoxyphenyl 74 2 0 Ethyl 3,4,5-Tris- (pi- ridin-4-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 75 2 0 3,4,5-Tris- (pi- ridin-4-yl- methoxy) phenyl Ethyl 3,4,5-Trimethoxyphenyl 76 2 0 Methyl 3,4,5-Tris- (pyrazin-2-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 77 2 0 Methyl 3,4,5-T fig- (pi- ridin-4-yl- methoxy) phenyl 3,4-Dimethoxyphenyl 78 2 0 Ethenyl 3,4,5-Tris- (pi- ridin-4-ylmethoxy) phenyl 3,4,5-Trimethoxyphenyl 79 2 0 3,4,5-T fig- (pi- ridin-4-yl- methoxy) phenyl Ethenyl 3,4,5-T rimethoxyphenyl 80 2 0 Prop 3,4,5-Tris- (pi- ridin-4-yl- methoxy) phenyl 3,4,5-T rimethoxyphenyl 81 2 0 3,4,5-T fig- (pi- ridin-4-yl- methoxy) phenyl Prop 3,4,5-Trimethoxyphenyl

Comp. η m in D Ah 82 2 0 Methyl 3,4,5-Tris- (thiophen-3-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 83 2 0 3,4,5-Tris- (thiophen-3-ylmethoxy) phenyl Methyl 3,4,5-T rimethoxyphenyl 84 2 0 Methyl 2-isopropoxy- 3,4-bis- (pyridin-4-ylmethoxy) -phenyl 3,4,5-T rimethoxyphenyl 85 2 0 2-isopropoxy- 3,4-bis- (pyridin-4-ylmethoxy) -phenyl Methyl 3,4,5-Trimethoxyphenyl 86 1 0 Methyl 3,4,5-Tris- (pi- ridin-4-ylmethoxy) phenyl 3,4,5-Trimethoxyphenyl 87 1 0 3,4,5-Tris- (pi- ridin-4-yl- methoxy) phenyl Methyl 3,4,5-Trimethoxyphenyl 88 2 0 Methyl 3,4,5-Tris- (pyridin-4-ylmethoxy) phenyl 3,4,5-T rimethoxyphenyl 89 2 0 Benzyloxymethyl Benzyloxy- phenyl 3,4,5-Trimethoxyphenyl 90 2 0 Methyl 3,4,5-T Fig. (benzyl oxy) - phenyl 3,4,5-T Rome ethoxyphenyl

Comp. η m in D Ah 91 2 0 3-Phenylpropyl 3- (pyridin-3-yl- carbonyl) phenyl 3,4,5-T rimethoxyphenyl 92 2 0 3- (pyridin-3-yl- carbonyl) phenyl 3-Phenylpropyl 3,4,5-T rimethoxyphenyl 93 2 0 3-Phenylpropyl 3- (pyridin-4-yl- methoxy) phenyl 3,4-Dimethoxyphenyl 94 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl 4-Benzyloxy-3,5- dimethoxyphenyl 95 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl 4-Allyloxy-3,5- dimethoxyphenyl 96 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl 3-Benzyloxy-4- methoxyphenyl 97 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl C-Allyloxy-4- methoxyphenyl 98 2 0 3-Phenylpropyl 3- (pyridin-4-ylcarbonyl) phenyl 3 - [- 3-phenyl- (E) -prop-2- enyl] -4-methoxyphenyl 99 2 0 3-Phenylpropyl 4- (pyridin-4-yl- carbonyl) phenyl 4-Benzyloxy-3,5- dimethoxyphenyl 100 2 0 3-Phenylpropyl 4- (pyridin-4-yl- carbonyl) phenyl 3-Benzyloxy-4- methoxyphenyl 101 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl 3,4,5-T Rome ethoxyphenyl 102 2 0 3-Phenylpropyl 3- (pyridin-4-yl- carbonyl) phenyl 3,4-Dimethoxyphenyl 103 2 0 3-Phenylpropyl Phenyl 3-Benzyloxy-4- methoxyphenyl 104 2 0 3-Phenylpropyl Phenyl 4-Benzyloxy-3,5-

dimethoxyphenyl

Syed. η m in D Ah 105 1 0 3- (Pyridin-3-yl) - wasted 3-Phenylpropyl tert-Butyl 106 2 0 3- (Pyridin-3-yl) - wasted 3- (Pyridine-3- yl) -propyl 3,4,5-T rimethoxyphenyl 107 1 0 Benzyloxymethyl Benzyloxy- phenyl 3,4,5-Trimethoxyphenyl 108 1 0 3- (Pyridin-3-yl) - wasted 3- (Iridium-3- yl) -propyl 3,4,5-Trimethoxyphenyl 109 2 0 3- (Pyridin-3-yl) - wasted 3- (Pyridine-3- yl) -propyl Isopropyl 110 2 0 3- (Pyridin-3-yl) - wasted 3- (Pyridine-3- yl) -propyl Thiophen-2-yl 111 2 0 3- (Pyridin-3-yl) - wasted 3- (Pyridine-3- yl) -propyl 3,4-Methylenedioxy- phenyl 112 2 0 3- (Pyridin-3-yl) - prop-2-ynyl 3- (Pyridine-3- yl) -prop-2-ynyl 3,4-Methylenedioxy- phenyl 113 2 0 3- (Pyridin-3-yl) - προη-2-ynyl 3- (Pyridine-3- yl) -prop-2-ynyl 3,4,5-T rimethoxyphenyl 114 2 0 3- (Pyridin-2-yl) - wasted 3- (Pyridine-2- yl) -propyl 3,4,5-T rimethoxyphenyl 115 2 0 Isopropyl 3,4,5-Tris- (pi- ridin-4-yl- methoxy) phenyl 3,4,5-Trimethoxyphenyl 116 2 0 3,4,5-Tris- (pi- ridin-4-yl- methoxy) phenyl Isopropyl 3,4,5-T rimethoxyphenyl 117 2 0 Prop-2-enyl 3,4,5-Tris- (pi- 3,4,5-T rimethoxyphenyl

ridin-4-ylmethoxy) phenyl

Comp. n m IN D_________________Ar_________

118 2 0 3,4,5-Tris- (p-Prop-2-enyl 3,4,5-trimethoxyphenyl ridin-4-ylmethoxy) phenyl

The most preferred compounds of this invention are (5) -1- (2-oxo-2 (3,4,5-trimethoxyphenyl) 4-pyridin-3-yl-1- (3-pyridin-3-yl) propyl-butyl ester. (acetyl) piperidine-2-carboxylic acid and 4-pyridin-3-yl-1- (3-pyridin-3-yl) propyl-butyl ester of (R) -1- (2-oxo-2 (3) , 4,5-trimethoxyphenyl) acetyl) piperidine-2-carboxylic acid, and also pharmaceutically acceptable derivatives thereof and mixtures thereof.

According to the present use, the compounds of this invention, including the compounds of the formula are defined to include their pharmaceutically acceptable derivatives, a pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, ester or salt of such ester of a compound according to * this invention or any another compound which, when administered to a patient, is capable of producing (directly or indirectly) a compound of this invention or a metabolite or a residue thereof characterized by the ability to ddarzhat, increase or restore sensitivity of MDR-cells to therapeutic or prophylactic agents or to prevent development of multi-drug resistance.

The compounds of this invention represented by formula (I)? can be obtained using any conventional technique. Preferably, these compounds are chemically synthesized from widely available starting materials such as alpha-amino acids. Modular and convergent methods for preparing these compounds are also preferred. In the convergence approach, for example, large fragments of the final product of the final stages of synthesis are joined, rather than adding small fragments to the growing molecular chain.

Scheme 1 illustrates a representative example of a convergent process for the preparation of compounds of formula (I '), which is a preferred subgroup of compounds of formula (I), where A is oxygen. The process involves esterification of a protected alpha-amino acid of formula (X), wherein P is a protecting group, with an alcohol of formula (XI). Protected alphaamino acids are well known in the art and many are commercially available. For example, conventional protecting groups and convenient methods for protecting amino acids are described in: T. W. Greene, R. G. M. Wuts, Protective Groups in Organic Chemistry, 2nd Ed., John Wiley and Sons, New York (1991) ). For the protection of the nitrogen atom, alkoxycarbonyl groups are preferred in the compounds of formula (X), and in particular tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), allyloxycarbonyl (Alloc) and trimethylsilylethoxycarbonyl (Theos).

After esterification, the compounds of formula (XII) are deprotected under appropriate conditions (see Greene above) and the free amine group of (XIII) is then acylated with a compound of formula (XIV) or an activated derivative thereof, whereby obtains a compound of formula (D). Methods for activating carboxylic function in carboxylic acids, such as those of formula (XIV), are well known and many activating agents are commercially available.

Alcohols of formula (XI), where m is 0 (XI ^ can also be conveniently obtained, for example as illustrated in Schemes 2 and 3. The reaction between an organometallic reagent of formula (XV) and an aldehyde of formula (XVI) results in alcohols of formula (XI ') (Scheme 2).

According to another alternative (Scheme 3), 1,6-heptadiin-4-ol may be coupled to aromatic halides of formula (XVII) by a metal-catalyzed reaction to give alcohols of formula

Scheme 1

Scheme 2 (XV) (XVI)

In — Metal +

Scheme 3

he

A /, ---- On!

+

Ar ₃ ---- On |

(XVIII) the texts (XVII) and Ar ^ are independently selected Ar groups as defined in * 1 'cat.

(XVIII). Subsequent hydrogenation yields alcohols of formula (XI '), a preferred subset of alcohols of formula (XI).

Thus, the present invention also provides a process for the preparation of compounds of formula (D), comprising the following steps:

a) esterifying a protected amino acid of (formula (X) with an alcohol of formula (XI) to afford the intermediate of formula (XII);

b) deprotecting the amino group of the intermediates of formula (XII) to obtain the amino ester of formula (XIII);

c) acylation of the free amino group of the compound of formula (XIII) by a compound of formula (XIV) or an activated derivative thereof.

Those of ordinary skill in the art will be able to understand that through the processes illustrated in the synthetic Schemes 1, 2 and 3 _; Many of the compounds of formula (I) can be readily prepared. The same procedures can be used to produce a large number of different end products by varying starting materials.

For example, compounds of formula (I ”) (not shown) where A is NH or N- (C 1 -C 4 alkyl) _? can be prepared by a peptide coupling reaction between a carboxylic acid of formula (X) and an amine of formula (XI '') (not shown) to give an amide of formula (XII '). This step is analogous to the first esterification reaction of Scheme 1. The steps leading from (ΧΙΓ) to (D) _? are analogous to those leading from (XII) to (D) shown in Scheme 1.

Optically active compounds of formula (I) may also be prepared using optically active starting materials, thereby avoiding the need to separate enantiomers or to separate diastereoisomers at later stages of synthesis.

Those of ordinary skill in the art will also be able to understand that the above synthetic schemes do not include all the possible ways in which the compounds or intermediates of this invention can be prepared. Other methods or modifications of the above general schemes will be apparent to those skilled in the art.

The compounds of the present invention can be modified by the addition of suitable functional groups to enhance their specific biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase diff ^_ vorimosgta to allow administration by injection, alter metabolism and change the excretion rate.

The compounds of the present invention are characterized by the ability to increase, restore or maintain the sensitivity of MDR cells to cytotoxic compounds, such as, for example, chemotherapy typically used. Based on this ability, the compounds of the present invention have been successfully used as chemosensitizing agents to enhance the effectiveness of chemotherapy in individuals under the influence of drug-resistant forms of cancer, tumors, metastases or other diseases. In addition, the compounds of the present invention are capable of maintaining the 'sensitivity of non-resistant cells to therapeutic or prophylactic agents. Therefore, the compounds of the present invention are useful in the treatment or prophylaxis of multidrug resistance in patients. The term "patient" as used herein refers to mammals, including humans. The term "cells" means mammalian cells, including human cells.

As used herein, the terms "sensitizing agent", "sensitizer", "chemosensitizing agent, chemosensitizer" and "MDR modifier" mean a compound that is capable of enhancing or restoring the sensitivity of MDR cells or maintaining the susceptibility of nonresistant cells or resistant cells more therapeutic or prophylactic agents. The term MDR-sensitization, "sensitization" and "sensitization" refers to the action of such a compound to maintain, enhance or restore sensitivity to drugs.

According to one of the ingredients of the present invention, the compounds of this invention that are useful for enhancing, restoring or maintaining drug sensitivity are also capable of binding to protein FKBP-12 or other related FK-506 binding proteins, such as FKBP- 13, FKBP-26 and FKBP-52. In vitro tests of these compounds (data not shown) demonstrate that the agents bind to FKBP-12. Thus, this invention also includes a class of chemosensitizing agents other than FK-506, which are characterized by the ability to bind to FK-binding protein-12 or to related FK-binding proteins; also include pharmaceutical compositions containing such agents and physiologically acceptable excipients, carriers and motors, as well as methods of using these compositions for the treatment or prophylaxis of multidrug resistance in patients.

Preferred compounds suitable for use in preventing or altering multidrug resistance are those which are not substantially immunosuppressed at clinically useful prophylactically or therapeutically active doses - i.e., their immunosuppressive effect (if any) does not dominate the value of the senses. activity of the compounds on the patient. Such immunosuppressant properties can be established by in vitro tests provided for in US Patent Nos. 07 / 547,814 (now U.S. Patent 5,192,773), 07 / 704,734, 07 / 697,785 and 07 / 881,152, which includes their detection.

The compounds of the present invention may be used in the form of pharmaceutically acceptable salts with inorganic or organic acids and bases. Such salts include, among others the following: acetates, adipates, alginates, aslartati, benzoates, benzenesulfonates, bisulfates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride , hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, oxalates, pamoates, pectinates, persulfates, 3-phenyl-propionates, picrates, pyvalates, pyvalates cinnates, tartarates, thiocyanates, tosylates and undecanoates. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, organic base salts such as dicyclohexylamine salts and N-methyl-O-glucamine, as well as amino acid salts such as arginine, lysine and so on. Also, the basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides, for example methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfate and, such as dimethyl, diethyl, dibutyl and diamyl sulfates; long-chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides such as benzyl and phenethyl bromides and the like. In this way, water- or oil-soluble or dispersion products are obtained.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, superficial, rectal, nasal, oral, vaginal or implanted reservoirs in the form of dosage formulations containing conventional non-toxic pharmaceutically acceptable carriers, excipients and excipients . The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions of the present invention include any of the compounds of this invention or a pharmaceutically acceptable salt thereof, as well as any pharmaceutically acceptable carrier, excipient or motor. Pharmaceutically acceptable carriers, excipients and motors that can be used in the pharmaceutical compositions of the present invention include, but are not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum protein , buffering agents such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, electrolyte salts such as protamine sulfate, disodium hydride ogenfosfat, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

According to the present invention, the pharmaceutical compositions can be in the form of sterile injectable preparations, for example, a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known to those skilled in the art using suitable dispersing or wetting and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenteral-acceptable diluent or solvent, for example a solution in

1, 3-butanediol. Acceptable vehicles and solvents that may be used include: water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile oils are conventionally used as solvents or suspension media. All sterile oils, including mono- and diglycerides, may be used for this purpose. Fatty acids such as oleic acid and its glyceride derivatives are also useful in the preparation of injectable preparations, as well as natural pharmaceutically acceptable oils such as olive oil or castor oil, especially in the form of their polyoxyethylated versions. These oily solutions or suspensions may also contain long-chain alcohols, such as Ph, as diluents or dispersants. Helv or similar alcohol.

The pharmaceutical compositions of the present invention can be administered orally in any orally acceptable dosage form, including (but not limited to) the following forms: capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers such as lactose and corn starch are usually included. Typically, lubricating agents such as magnesium stearate are also added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying or suspending agents. If desired, some sweeteners, flavors and dyes may also be added.

Alternatively, the pharmaceutical compositions of the present invention may be administered rectally in the form of suppositories. They can be prepared by mixing the agent with a suitable non-irritant that is solid at room temperature and liquid at rectal temperature so that it melts into the rectum and releases the drug. Such materials include cocoa butter, beeswax and polyethylene glycol.

The pharmaceutical compositions of the present invention may also be applied topically, especially when the subject of treatment includes surfaces or organs that are readily available for topical application: diseases of the eye, skin or lower digestive tract. Suitable surface application formulations are readily prepared for each of these surfaces or organs.

Superficial applications to the lower gastrointestinal tract may be realized by rectal suppository forms (see above) or by suitable enema forms. Surfaces that penetrate the skin may also be used.

Pharmaceutical compositions for topical administration may also be formulated as a suitable ointment containing the active ingredient which is suspended or dissolved in one or more carriers. Carriers for the topical administration of compounds of this invention include (but are not limited to) the following: mineral oils, petroleum liquid, white petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsion wax and water. Alternatively, the pharmaceutical compositions may be formulated as a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include (but are not limited to) the following: mineral oils, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,

2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH-adjusted and sterile saline, or preferably as solutions in isotonic, pH-adjusted and sterile saline, with or without the addition of a stabilizer such as benzylalkonium chloride. Alternatively, pharmaceutical compositions for ophthalmic use may be formulated as petroleum-based ointments.

The pharmaceutical compositions of the present invention may also be administered via the nose such as aerosols or inhalations. Such compositions are formulated using techniques well known in the art and may be prepared by dissolving in saline, using a benzyl oval shell or other suitable stabilizers, absorption promoters aimed at enhancing bioavailability, fluorocarbons and / or conventional solubilizing or dispersing agents.

The amount of active ingredient that can be combined with carrier materials to produce a single dose should vary depending on the subject of treatment and the particular route of administration. However, it should be borne in mind that the specific dose and treatment regimen for each individual patient will depend on a number of factors including the activity of the particular compound used, age, body weight, general health, gender, diet, timing, rate the separation, the combination of medicines and the judgment of the treating physician, and the severity of the specific disease being treated. The amount of active ingredient may also depend on the therapeutic or prophylactic agent (if any) that is co-administered with the ingredient. The term 'pharmaceutically effective amount' used herein refers to an amount that is effective for preventing multidrug resistance or for maintaining, increasing or restoring drug sensitivity in MDR cells.

The useful dosage levels of the active ingredient are between 0.01 and about 100 mg / kg body weight per day, preferably between about 0.5 and about 50 mg / kg body weight per day. A typical preparation will contain between about 5% and about 95% (w / w) of the active substance. Preferably, such preparations contain between about 20% and about 80% active ingredient.

When the compounds of the present invention are administered in combination therapy with other agents, they may be administered sequentially or simultaneously to the patient. Alternatively, the pharmaceutical or prophylactic compositions of the present invention may include a combination of a compound of the present invention and another therapeutic or prophylactic agent.

For example, the compounds can be administered either alone or in combination with one or more therapeutic agents, such as chemotherapeutic agents (e.g. actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipazide, taxol and colchicine) chemosensitizing agents (eg cyclosporin A and analogues, fentiazines and thioxanthrenes) in order to increase the susceptibility of the patient's MDR cells to the agent or agents.

In order to fully understand the present invention, the following examples are provided. These examples are by way of illustration only and should not be construed to limit the scope of the invention in any way.

EXAMPLES FOR THE IMPLEMENTATION OF THE INVENTION

General methods

Proton magnetic resonance spectra (1 H NMR) were taken at 500 MHz on a Bruker AMX 500 spectrometer. Chemical shifts are given in million parts (c) relative to Me ₄ Si (δ = 0.0). Analytical high performance liquid chromatography (HPLC) was performed with Waters 600E or Hewlett Packard 1050 liquid chromatographs.

Example 1

Preparation of ($) - 1,7 «Diphenyl-4-heptanyl N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (3)

4-Phenyl-1-butyraldehyde (119). To a solution of 3.2 ml (20.8 mmol) of 4-phenyl-1-butanol (Aldrich Chemical Co.) in 20 ml of CH ₂ Cl ₂ at 0 ° C was added

3.2 g powder molecular sieve 3 A and then 5.37 g (24.9 mmol) pyridine chlorochromate (PCC). The resulting suspension was stirred for 1 hour at 0 ° C, during which time an additional 2.16 g (10 mmol) of PCC was added and the reaction mixture was warmed to room temperature. After stirring for 0.5 h at room temperature, the reaction mixture was diluted with ether and filtered through celite to give 2.5 g of crude product. Flash chromatography (eluting with 5% ethyl acetate in hexane) afforded 700 mg of aldehyde 119. The ¹ H NMR spectrum was consistent with the structure.

3-Phenyl-1-propylmagnesium bromide (120). To a suspension of 736 mg (30.3 mmol) of magnesium chips in 50 ml of tetrahydrofuran (THF) at room temperature was added 50 µl of 1,2-dibromoethane, and then 5.5 g (25.1 mmol) 1 was added dropwise, -bromo-3-phenylpropane (Aldrich Chemical Co.). After stirring for 0.5 h at room temperature, the liquid layer was transferred by a drainage tube into a 100 ml vessel and subsequently used as a 0.5 M solution in THF of Grignard'oenn reagent 120.

1,7-Diphenyl-4-heptanol (121). To a solution of 700 mg (4.7 mmol) of 4-phenyl-1-butanol (119) in 5 ml of THF at 0 ° C was added 10.5 ml (5.0 mmol)

3-phenyl-1-propylmagnesium bromide (120) and the resulting mixture was stirred for 0.5 h at 0 < 0 > C. The reaction was then quenched by the addition of saturated NH ₄ Cl solution and diluted with ether. The phases were separated and the organic layer was washed with water and brine, then dried over MgSO ₄ . Concentration gave 1.12 g of alcohol 121 as an oil. ^{The 1} H NMR spectrum is consistent with the structure.

(S) -Boc-1-Pipecolyl-1,7-diphenyl-4-heptanyl-ester (122). To a solution of 164 mg (0.72 mmol) of Boc-L-pipecolic acid in 5.0 ml of CH ₂ Cl ₂ at room temperature was added 174 mg (0.65 mmol) of alcohol 121, 140 mg (0.72 mmol) ) 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and a catalytic amount of N, N-dimethylaminopyridine (DMAP). The reaction mixture was stirred for 0.5 h at room temperature and then applied directly to a silica gel column. Elution with 10% ethyl acetate in hexane afforded 76.2 mg of ester 122 as an oil. ^{The 1} H NMR spectrum agrees with the structure.

(S) -1,7-Diphenyl-4-heptanylpiperate (123). To a solution of 47 mg (0.10 mmol) of ester 122 in 1.0 ml of CH ₂ Cl ₂ at room temperature was added 1.0 ml of trifluoroacetic acid. After stirring for 0.5 h at room temperature, the resulting solution was neutralized by invocation of saturated K _; CO ₃ . The layers were separated and the organic phase was washed with water, dried over MgSO ₄ and concentrated to give 23 mg of amine 123 as an oil. The 1 H NMR spectrum is consistent with the structure.

3,4,5-Trimethoxybenzoyl formic acid (124). To a solution of 9.2 g (43.4 mmol) of 3,4,5-trimethoxyacetophenone (Aldrich Chemical Co) in 35 ml of pyridine was added 6.3 g (56.7 mmol) of selenium dioxide and the resulting solution was reversed. fridge overnight. The resulting mixture was cooled to room temperature, filtered through celite and concentrated to give a dark brown oil. The latter was dissolved in ethyl acetate and washed with 0.1 N HCl and then with saturated NaHCO ₃ solution. The alkaline aqueous layer was diluted with ether and acidified with concentrated HCl). The layers were separated and the organic phase was washed with brine and dried over Na ₂ SO ₄ to give 8.4 g of acid 124 as a light yellow solid. ^{The 1} H NMR spectrum is consistent with the structure.

(S) -1,7-Diphenyl-4-heptanyl N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (3). To a solution of 23 mg (0.06 mmol) of amine 123 in 1.0 ml of CH ₂ Cl ₂ at room temperature was added 21.8 mg (0.09 mmol) of acid 124 and then 17.9 mg (0 , 09 mmol) EDC, after which the resulting solution was stirred for 0.5 h at room temperature and developed directly on a silica gel column. Elution with 15% ethyl acetate in hexane gave 8.4 mg of amide 3 as a mixture of rotamers. ¹ H NMR spectrum (500 MHz in CDCI ₃ ): δ 7.35-7.06 (m), 5.32 (br s), 5.00 (br s), 4.88 (br s), 4.58 (d), 4.31 (br s), 3.95 (s), 3.89 (s), 3.44 (d), 3.21 (t), 3.04 (t), 2.54 (br s), 2.51 (br s), 2.42 (br s), 2.30 (d), 2.15 (d), 1.83-1.21 (m).

OM ·

Example 2

Preparation of (R and 8) -1- (3-phenoxy) phenyl-4-phenyl-1-butyl (S) - N- (3,4,5 trimethoxyphenyl-glyoxyl) pipecolate (4)

C-Phenoxybenzaldehyde (125). To a solution of 1.8 ml (10.3 mmol) of 3-phenoxybenzyl alcohol (Aldrich Chemical Co.) in 20 ml of CH ₂ Cl ₂ at room temperature was added 1.5 g of a powdered molecular sieve 4A and 2.5 g of activated MnO ₂ . The resulting suspension was stirred for 0.5 h at room temperature, during which time an additional 2.5 g of MnO ₂ was added. After stirring for 0.5 h at room temperature, the reaction mixture was filtered through celite to give 1.84 g of aldehyde 125 as an oil. ^{The 1} H NMR spectrum is consistent with the structure.

(R and S) -1- (3-Phenoxy) phenyl-4-phenyl-1-butanol (126). Alcohol 126 was prepared from 190 mg (0.96 mmol) of aldehyde 125 and 2.0 ml (1.0 mmol) of Grignard'oB reagent 120 in 2.0 ml of THF as described above for the preparation of alcohol 121 in Example 1. Flash chromatography (eluting with 10% ethyl acetate in hexane) gave 108 mg of racemic alcohol 126. The ¹ H NMR spectrum was consistent with the structure.

(S) - N- (3,4,5-trimethoxyphenyl) glyoxyl-pipecolic acid (127) To a mixture of 953.3 mg (3.4 mmol) tartrate salt of (S) -pipecolic acid (Egbertson.M. And Danishefsky, SJ, J, Orq. Chem. 1989, 54.11) in 7.0 ml of CH ₂ Cl ₂ at 0 ° C was added 3.9 ml (22.39 mol) of diisopropylethylamine and

2.4 ml (18.9 mmol) of trimethylchlorosilane, after which the resulting solution was stirred for 0.5 h at 0 ° C. In a separate flask, to a solution of 820 mg (3.4 mmol) of acid 124 in 7.0 ml of CH ₂ Cl ₂ were added 450 pL (5.2 mmol) of oxalyl chloride and 3 drops of dimethylformamide (DMF). After stopping gas evolution, the contents of the second flask were added to the first reaction vessel and the resulting mixture was stirred for 1 hour at room temperature.

The reaction mixture was concentrated, dissolved in ether and washed with 0.5 N HCl and then with saturated NaHCO ₃ solution. The basic aqueous phase was acidified with concentrated HCl and extracted with ether. The ether extracts were washed with water and brine, dried over MgSO ₄ and concentrated to give 490 mg of the acid 127. The ¹ H NMR spectrum was consistent with the structure.

(R and 3) -1- (3-phenoxy) phenyl-4-phenyl-1-butyl (S) · N- (3,4,5 trimethoxyphenyl-glyoxyl) pipecolate (4). To a solution of 29.4 ml (0.08 mmol) of the acid 127 in 2.0 ml of CH ₂ Cl ₂ at room temperature was added 11 pL (0.13 mmol) of oxalyl chloride and three drops of DMF, after which the reaction mixture was stirred. 0.5 h at room temperature and then concentrated and suspended in 1.0 ml of benzene. 32.0 mg (0.1 mmol) of alcohol 126 and 13.4 mg (0.1 mmol) of silver cyanide were added to the suspension. The resulting mixture was refluxed overnight, cooled to room temperature and concentrated. Flash chromatography (eluting with 10% ethyl acetate in hexane) afforded 8.8 mg of ester 4 as a mixture of diastereoisomers. ¹ H NMR (500 MHz in CDCI ₃ ): δ 7.34-7.19 (m), 7, fl87.03 (m), 7.02-6.84 (m), 6.83-6 , 72 (m), 5.73 (q), 5.69-5.55 (m), 5.38 (t), 4.55 (bd), 4.35 (dd), 3.94 (s ), 3.92 (s), 3.89 (s), 3.83 (s), 3.73 (s), 3.63 (s), 3.48-3.35 (m), 3. 20 (t), 3.10 (t), 2.60 (q), 2.40 (dd), 1.95-1.91 (m), 1.90-1.45 (m).

ΟΜ »

Example 3

Preparation of (R and 8) -6-Phenyl-1- (3-pyridyl) -3-hexyl (S) - N- (3,4,5 trimethoxyphenyl-glyoxyl) pipecolate (7)

3- (3-Pyridyl) -1-propyl aldehyde. To a solution of 2.3 g (5.46 mmol) of Dess-Martin periodinine (Dess, D. B., Martin, JC, J. Org. Chem. 1983, 48, 4155) in 10 ml of CH ₂ Cl ₂ at 470 pL (3.65 mmol) of 3- (3-pyridyl) -1-propanol are added at 0 ° C and the reaction mixture is allowed to warm from 0 ° C to room temperature for 1.5 hours. To the solution was added 6.0 g (38.22 mmol) of Na ₂ S ₂ O ₃ in saturated NaHCO ₃ and the reaction mixture was stirred for 15 min at room temperature. The mixture was extracted with CH ₂ Cl ₂ , dried over MgSO ₄ and concentrated. Flash chromatography (eluting with hexane: acetone 3: 1) gave the aldehyde 128 as an oil. ^{The 1} H NMR spectrum is consistent with the structure.

(R and S) -6-phenyl-1- (3-pyridyl) -3-hexanol (129). Alcohol 129 was obtained from 125 mg (0.92 mmol) of aldehyde 128 and 2.0 ml (1.0 mmol) of compound 120 in 2.0 ml of THF as described above for the preparation of alcohol 121 in Example 1. This gives 221 mg of the raw alcohol 129. The ¹ H NMR spectrum is consistent with the structure.

(S) -Boc-Pipecolyl- (R and S) -6-Phenyl-1- (3-pyridyl) -3-hexyl-ester (130). The ester 130 is obtained from 125 mg (0.49 mmol) of alcohol 129, 93 mg (0.41 mmol) of Boc-pipecolic acid, 94 mg (0.49 mmol) of EDC and a catalytic amount of DMAP in 1.0 ml of CH ₂ Cl ₂ and 1.0 ml of DMF as described above to give compound 122 in Example 1. Flash chromatography (eluting with hexane: ethyl acetate 2: 1) gave 105 mg of diastereoisomer ester 130 as an oil. The 1 H NMR spectrum is consistent with the structure.

(R and S) -6-Phenyl-1- (3-pyridyl) -3-hexyl (S) -pipecolate (131). Amine 131 was synthesized by treating 95 mg (0.20 mmol) of ester 130 with 1.0 ml of trifluoroacetic acid in 3.0 ml of DMF, as described above, to obtain amine 123 in Example 1. Thereto, 58 mg of the diastereomeric amine 131 as an oil. ^{The 1} H NMR spectrum agrees with the structure.

(R and 5) -6-Phenyl-1- (3-pyridyl) -3-hexyl (S) - N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (7). The ester 7 was obtained from 54 mg (0.15 mmol) of amine 131, 50 mg (0.22 mmol) of acid 124 and 42 mg (0.22 mmol) of EDC in 3.0 ml of CH ₂ Cl ₂ as described above for the preparation of ester 3 in Example 1. Flash chromatography (eluting with hexane-ethyl acetate 1: 1) afforded 73 mg of diastereoisomer ester 7 as a mixture of rotamers. 1 H NMR (500 MHz in CDCl 3): δ 8.48-8.42 (m), 7.50-7.41 (m), 7.32 (d), 7.27-7.03 ( m), 5.38 (d), 5.31 (d), 5.06-5.01 (m), 4.97-4.93 (m), £ 4 0 (br d), 3.92 (s), 3.88 (s), 3.86 (s), 3.84 (s), 3.82 (s), 3.79 (s), 3.46 (br t), 3.27 (br t), 2.73-

2.68 (m), 1.98-1.76 (m), 1.75-1.60 (m), 1.56-1.51 (m), 1.38-1.20 (m) .

Example 4

Preparation of (R and 8) - (E) -1- [trans- (4-hydroxycyclohexyl)] - 2-methyl-6 · phenyl-3-hex-1-enyl (S) -1M- (3,4, 5-trimethoxyphenyl-glyoxyl) pipecolate (8)

Cis- and trans-4- (tert-butyldimethylsilyloxy) -cyclohexan-1-ol (132 and 133). To a solution of 3.43 g (21.7 mmol) of 4-hydroxy-cyclohexanecarboxylic acid cis- and trans-methyl ester (Noyce, DS, Denney, DV, J. Am. Chem. Soc. Vol. 74, 5912 (1952)) in 45 ml of CH ₂ Cl ₂ at 0 ° C was added 3.0 ml (26.0 mmol) of 2,6-lutidine followed by 5.5 ml (23.0 mmol) of tert-butyldimethylsilyl-trifluoromethanesulfonate. The ice bath was removed and the reaction mixture was stirred for 2 hours at 25 ° C, after which the solution was poured into saturated sodium bicarbonate solution. The layers were separated and the organic layer was washed with saturated copper sulfate solution and water and dried over MgSO ₄ . 5.9 g of crude methyl ester are obtained. Solution of

5.72 g (21.0 mmol) of this mixture in 45 ml of anhydrous THF was treated with 400 mg (10.5 mmol) of lithium aluminum hydride. The reaction mixture was stirred for 0.5 hour at 25 ° C, after which the reaction was terminated by slow addition of saturated Rochelle'oea salt solution. The mixture was diluted with ether, the layers were separated and the aqueous layer was washed twice with ethyl acetate. The combined organic extracts were dried over MgSO ₄ and concentrated to give 4.9 g of diastereoisomeric alcohols. Flash chromatography (eluting with hexane: ethyl acetate 5: 1) afforded 650 mg of compound 132, 1.10 g of 133 and 2.40 g of a mixture of the two compounds. Compound data 132: H NMR (300 MHz in CDCI ₃ ): δ 3.99-3.92 (m), 3.46 (d), 1.72-1.58 (m), 1.57 -1.36 (m), 0.86 (s), 0.08 (s). Data for compound 133: ¹ H NMR (300 MHz in CDCI ₃ ): δ 3.47 (dddd), 3.38 (d), 1.86-1.67 (m), 1.47-1, 16 (m), 1.05–0.77 (m), 0.72 (s), 0.02 (s).

(E) -Ethyl 3- [trans-4- (tert-butyldimethylsilyloxycyclohexyl)] -2methylprop-2-enoate (134). Dimethyl sulfoxide (1.3 ml, 18.0 mol) was added to a solution of oxalyl chloride (785 ml, 9.0 mmol) in 10 ml of CH ₂ Cl ₂ at -78 ° C. The resulting solution was stirred for 5 min and then 1.1 g (4.5 mmol) of alcohol 133 in 10 ml of CH-Cl _{2 was added} . The reaction mixture was stirred at -78 ° C for 45 min, then 3.8 ml (27.0 mmol) of triethylamine were added and the solution was allowed to warm to room temperature. The reaction was quenched with 1.0 N HCl and the aqueous layer extracted with three portions of methylene chloride. The combined organic extracts were dried over MgSO ₄ and evaporated to dryness to give 1.0 g of the intermediate aldehyde. A solution of this aldehyde (450 mg, 1.86 mmol) was treated directly with 710 mg (1.95 mmol) (carbethoxyethylidene) triphenylphosphorane in 5.0 ml of methylene chloride. The resulting reaction mixture was stirred at room temperature overnight and then poured into water. The layers were separated and the aqueous layer was extracted twice with methylene chloride. The combined organic extracts were dried over MgSO ₄ and concentrated to give the enol 134 containing a small amount of the Z-isomer. ^{The 1} H NMR spectrum is consistent with the structure.

(E) -3- (trans-4- (tert-butyldimethylsilyloxycyclohexyl)] - 2-methylprop-

2-en-1-ol (135). To a solution of 860 mg (2.6 mmol) of enoate 134 in 5 ml of anhydrous tetrahydrofuran at 25 ° C was added 50 mg (1.3 mmol) of lithium aluminum hydride and the reaction mixture was stirred for 30 min. The reaction was stopped by slow addition. saturated Rochelle'oBa salt solution and the mixture was diluted with ethyl acetate. The layers were separated and the aqueous layer was extracted with two portions of ethyl acetate. The combined orthan extracts were washed with water and brine, then dried over MgSO ₄ . Evaporation and flash chromatography (eluting with 15% ethyl acetate in hexane) gave 370 mg of allyl alcohol 135. The ¹ H NMR spectrum was consistent with the structure.

(E) -3- [trans-4- (tert-butyldimethylsilyl oxycyclohexyl)] - 2-methylprop-

2-en-1-al (136). To a solution of oxalyl chloride (105 µl, 1.2 mmol) in 1.0 ml of CH ₂ Cl ₂ at -78 ° C was added dimethyl sulfoxide (170 µl, 2.4 mol). The resulting solution was stirred for 5 min and then 170 mg (0.6 mmol) of alcohol 135 in 1.0 ml of CH ₂ Cl _{2 was added} . The reaction mixture was stirred at -78 ° C for 45 min, then 500 µl (3.6 mmol) of triethylamine was added and the solution was allowed to warm to room temperature. The reaction was quenched with 1.0 N HCl and the aqueous layer extracted with three portions of methylene chloride. The combined organic extracts were dried over MgSO ₄ and evaporated to dryness to give the crude aldehyde 136, which was used immediately in the next reaction. Ή The NMR spectrum agrees with the structure.

(R and S) - (E) -1- [trans-4- (tert-butyldimethylsilyloxycyclohexyl) 1-2methyl-6-phenylhex-1-en-3-ol (137). Alcohol 137 was obtained from the crude aldehyde 136 and 1.5 ml (0.75 mmol) of compound 120 in 2.0 ml of THF as described above to afford the alcohol 121 in Example 1. This gave 220 mg of crude diastereoisomeric alcohol 137. Flash chromatography (eluting with 20% ethyl acetate in hexane) gave 146 mg of alcohol 137 as an oil. The 1 H NMR spectrum is consistent with the structure.

(R and 5) - (E) -1- [trans- (4-tert-butyldimethylsilyloxycyclohexyl)] -2methyl-6-phenyl-3-hex-1-enyl (S) - b1- (3,4,5- trimethoxyphenylglyoxyl) pipecolate (138). To a solution of 75.5 mg (0.22 mmol) of acid 127 in 2.5 ml of CH ₂ Cl ₂ at room temperature was added 30 µl (0.34 mmol) of oxalyl chloride and three drops of DMF, after which the reaction mixture was stirred. 0.5 h at room temperature and then concentrated and suspended in 1.0 ml of benzene. 43.4 mg (0.11 mmol) of alcohol 137 and 28.8 mg (0.22 mmol) of silver cyanide were added to the suspension. The resulting mixture was refluxed overnight, cooled to room temperature and concentrated. Flash chromatography (eluting with 4% acetone in hexane) afforded 17.5 mg of ester 138 as a mixture of diastereoisomers. ^{The 1} H NMR spectrum is consistent with the structure.

(R and 5) - (E) -1- [trans- (4-hydroxycyclohexyl)] -2-methyl-6-phenyl-3-hex-

1-enyl (S) - N- (3,4,5-trimethoxyphenyl-glyoxyl) pipecolate (8). To a solution of 17.5 mg (0.02 mmol) of ester 138 in 1.0 ml of CH ₃ CN at room temperature was added 10 drops of a 95: 5 solution of CH ₃ CN: 5% HF, followed by the reaction mixture stirred for 0.5 h at room temperature. The reaction mixture was neutralized with saturated K ₂ CO _{3 solution} and extracted with ether. The ether extracts were washed with water, dried over MgSO 4 and concentrated to give 7.2 mg of crude material. Flash chromatography (eluting with 15% acetone in hexane) gave 4.9 mg of the diastereoisomeric alcohol 8 as a mixture of rotamers. ¹ H NMR (500 MHz, CDCI ₃ ): δ 7.38-7.02 (m), 5.35-5.01 (m), 4.62-4.53 (m), 4.28 (t), 3.95 (s), 3.89 (s), 3.87 (s), 3.86 (s), 3.85 (s), 3.81 (s), 3.55 ( m),

3.45 (t), 3.20 (t), 3.10-2.90 (t), 2.60-2.45 (t), 2.32 (t), 2.10 (t), 1.95 (d), 1.85- 1.40 (t), 1.39-1.02 (cm). Art U. Λ ϊ

Example 5

Preparation of (R and S) - 5- (3-indolyl) -1-0-vinyl-2-pentyl- (3) - N- (3,4,5 trimethoxyphenyl-glyoxyl) pipecolate (11)

N-Methyl-N-methoxy-4- (3-indolyl; butyramide (139) To a mixture of 1.75 g (8.61 mmol) of 3-indole butyric acid (Aldrich Chemical Co) in acetonitrile at room temperature was added 7 , 0 ml (40.2 mmol) Ν, Νdiisopropylethylamine, 3.3 g (21.5 mmol) Ν, Ν-dimethylhydroxylamine hydrochloride and 4.19 g (9.5 mmol) of benzotriazol-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate (BOP reagent) and the resulting mixture was stirred at room temperature overnight, then concentrated to dryness, the residue was dissolved in ethyl acetate and washed with water, 0.5 N HCl, saturated NaHCO solution, and brine. , after which was dried over MgSO ₄ and concentrated to give 2.0 g of the amide 139. Flash chromatography (gradient elution with 2-10% ether in methylene chloride) gave ¹ H NMR spectrum consistent with the structure.

Benzyl-3- (3-indolyl) propyl ketone (140). To a solution of 147 mg (0.60 mmol) of amide 139 in 4.0 ml of THE at -78 ° C was added 1.31 ml (1.31 mmol) of benzylmagnesium chloride (1.0 M in ether) and the reaction mixture was added. allow to warm to room temperature, then stir for 3 hours. The reaction was quenched with 5% KHSO ₄ and extracted with ether. The combined ether layers were washed with brine and dried over MgSO ₄ . Flash chromatography (eluting with 25% ether in hexane) afforded 108 mg of ketone 140. The 1 H NMR spectrum was consistent with the structure.

(R and S) -5- (3-indolyl) -1-phenyl-2-pentanol (141). To a mixture of 105 mg (0.38 mmol) of ketone 140 in 3.0 ml of MeOH at 0 ° C was added 30 mg (0.79 mmol) of solid NaBH ₄ and the resulting suspension was stirred for 3 hours. The reaction was quenched with 5% KHSO ₄ and extracted with ethyl acetate. The combined organic extracts were washed with brine and dried over MgSO ₄ . Flash chromatography (eluting with 4% ether in methylene chloride) afforded 81 mg of alcohol 141 as a white solid. Ή The NMR spectrum agrees with the structure.

(S) -Boc-pipecolyl- (I and S) -5- (3-indolyl) -1-phenyl-2-pentyl ester (142). The ester 142 is obtained from 80 mg (0.29 mmol) of alcohol 141, 82 mg (0.36 mmol) (S) -Boc-pipecolic acid, 66 mg (0.34 mmol) EDC with a catalytic amount of 4-pyrrolidinopyridine in 2 , 0 ml of methylene chloride with stirring overnight at room temperature as described above for the preparation of ester 122 in Example 1. Flash chromatography (eluting with ether: methylene chloride: hexane 4:10:26) afforded 108 mg of diastereoisomeric ester 142 in the form of white foam. ^{The 1} H NMR spectrum agrees with the structure.

(R and S) -5- (3-indolyl) -1-phenyl-2-pentyl- (S) -__-pipecolate hydrochloride salt (143). Through a solution of 103 mg (0.21 mmol) of the ester

14D in 10 ml of ethyl acetate was purged with dry HCl for 10 min at -20 ° C, after which the reaction mixture was purged with N ₂ . Concentration afforded 108 mg of crude amine 143 as the hydrochloride salt. The 1 H NMR spectrum is consistent with the structure.

(R and 5) -5- (3-indolyl) -1-phenyl-2-pentyl - (S) - N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (11). To a mixture of 108 mg of crude amine 143 as the hydrochloride salt and CH ₃ CN at room temperature were added 91 jutn (0.31 mmol) of N, N-diisopropylethylamine, 76 mg (0.31 mmol) of acid 124 and 111 mg ( 0.25 mmol) of the BOP reagent and the resulting mixture was stirred at room temperature for two days, then concentrated to dryness. The residue was washed with 75 ml of ethyl acetate and washed sequentially with water, 5% KHSO ₄ , saturated NaHCCX solution and brine, then dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 4% ether in methylene chloride) afforded 56.7 mg of the diastereoisomer amide 11 as a mixture of rotamers. ¹ H NMR (500 MHz, COCl ₃ ): δ 7.98 (d), 7.56 (t), 7.38-6.73 (m), 5.38-5.14 (m) , 3.90 (m), 3.38 (br t), 3.10 (br t), 2.97-2.60 (m), 2.31 (d), 2.10 (d), 1 , 98-1.17 (m), 0.8 (m). R _f 0.51 (10% ether in methylene chloride).

Example 6

Preparation of (R and 5) -2-benzyl-4-phenyl-1-butyl- (S) - N- (3,4,5-trimethoxyphenyl-glyoxyl) pipecolate (16) (R and 5) -2-benzyl-4 -phenyl-1-butyric acid (144). To a solution of 1.06 g (6.43 mmol) of 4-phenyl butyric acid in 20 ml of THF at 0 ° C was added 193 mg (6.43 mmol) of solid NaH (80% in mineral oil). After stirring at 0 ° C for 0.5 h, 3.2 ml (6.43 mmol) of lithium diisopropylamide-THF complex (2.0 M) were added and the resulting red solution was stirred for 45 min at 0 ^with C. To the mixture was added. 765 ml (6.43 mmol) of benzyl bromide and the solution was stirred overnight at room temperature. The reaction was quenched by the slow addition of saturated NaHCO 3 solution and washed with ether. The basic extracts were acidified with solid KHSO ₄ and partitioned with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated to give 484 mg of the acid 144. The H NMR spectrum was consistent with the structure.

(R and 3) -2-benzyl-4-phenyl-1-butanol (145). To a solution of 469 mg (1.84 mmol) of acid 144 in 3.0 ml of THF at -78 ° C was added 2.03 ml (2.03 mmol) of lithium aluminum hydride (1.0 M in THF) and the resulting solution allowed to warm to room temperature, then stirred overnight. The reaction was quenched by the slow addition of Rochelle'oBa salt and the mixture was washed with ether. The combined ether extracts were washed with water and brine, dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 2% ether in methylene chloride) afforded 264 mg of alcohol 145. The NMR spectrum was consistent with the structure.

(3) -Boc-pipecolyl- (I and 3) -2-benzyl-4-phenyl-1-butyl ester (146). The ester 146 is prepared from 264 mg (1.10 mmol) of alcohol 145, 302 mg (1.32 mmol) of (S) -Boc-L-nonneoxyHOBa acid, 253 mg (1.32 mmol) of EDC with a catalytic amount of 4-pyrrolidinopyridine in 2 , 0 ml of methylene chloride with stirring for 3 days at room temperature as described above for the preparation of ester 122 in Example 1. Flash chromatography (eluting with ether: methylene chloride: hexane 1: 5: 14) afforded 375 mg of diastereoisomeric ester 146. The ¹ H NMR spectrum is consistent with the structure.

(R and 5) -2-Benzyl-4-phenyl-1-butyl- (S) -pipecolate hydrochloride salt (147). Through a solution of 375 mg (0.83 mmol) of ester 146 in 10 ml of ethyl acetate, purge dry HCl for 10 min at -20 ^g C, then purge the reaction mixture with N ₂ . Concentration gave 352 mg of the crude amine 147 as the hydrochloride salt. The H NMR spectrum is consistent with the structure.

(R and S) -2-Benzyl-4-phenyl-1-butyl- (S) -N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (16). To a mixture of 54 mg of crude amine 147 as the hydrochloride salt and 2.0 ml of CH ₃ CN at room temperature were added 60 ml (0.35 mmol) of N, N-diisopropylethylamine, 50 mg g (0.21 mmol) of acid 124 and 73 mg (0.16 mmol) of the BOP reagent and the resulting mixture was stirred at room temperature for 3 days, then concentrated to dryness. The residue was washed with 75 ml of ethyl acetate and washed sequentially with water, 5% KHSO ₄ , saturated NaHCO ₃ solution and brine, then dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 2% ether in methylene chloride) afforded 52.7 mg of the diastereoisomeric amide 16 as a mixture of rotamers. 1 H NMR spectrum

oh »

Example 7

Preparation of (R and 8) -1-phenyl-7- (2-pyridyl) -4-heptyl- (S) -N- (tert-butylglyoxyl) pipecolate (21) (E and Z) -3- (1, 3-Dioxan-2-yl) -1- (2-pyridyl 1-propene (148 and 149) To a suspension of 4.6 g (10.2 mmol) [2- (1,3-dioxan-2-yl) ) ethyl] triphenylphosphonium bromide (Aldrich Chemical Co) in 50 ml of THE at 0 ° C was added

6.4 ml (10.2 mmol) of n-butyllithium (1.6 M in hexane) and the resulting red solution was stirred for 0.5 h at 0 ° C. To the solution was added 880 pL (9.3 mmol) of pyridinecarboxaldehyde (Aldrich Chemical Co). The reaction mixture was stirred for 1 hour at room temperature, then poured into water and partitioned with ether. The combined ether extracts were dried over MgSO ₄ and concentrated. Flash chromatography (eluting with hexane: ethyl acetate 3: 1) afforded 0.43 g of E-3- (1,3-dioxan-2-yl) -1- (2-pyridyl) -1-propene (148 ) and 1.12 g of Z- (3- (1,3-dioxan-2-yl) -1- (2-pyridyl) -1-propene (149). ¹ H NMR spectrum consistent with the structure.

1- (1,3-Dioxan-2-yl) -1- (2-pyridyl) propane (150). A constant stream of hydrogen was purged through a suspension of 800 mg (4.2 mmol) of olefin 149 and 100 mg of 10% palladium-on-carbon over a period of 10 minutes. The reaction mixture was then filtered through celite and concentrated to give 805 mg of acetal 150 as a colorless oil. ^{The 1} H NMR spectrum is consistent with the structure.

4- (2-Pyridyl) -1-oil aldehyde (151). A solution of 420 mg (2.2 mmol) of acetal 151 in 4.0 ml THF and 3.0 ml 4N HCl was stirred for 1.5 hours at room temperature and then neutralized by slow addition of solid NaHCO ₃ . The reaction mixture was extracted with ethyl acetate, dried over MgSO ₄ and concentrated to give 288 mg of aldehyde 151. The ¹ H NMR spectrum was consistent with the structure.

(R and S) -1-phenyl-7- (2-pyridyl) -4-heptanol (152). Alcohol 152 was obtained from 288 mg (1.93 mmol) of aldehyde 151 and 2.3 ml (2.3 mmol) of compound 120 in 3.0 ml of THF, as described above in the preparation of alcohol 121 in Example 1. 520 mg of crude alcohol is obtained 152. Ή The NMR spectrum is consistent with structure / rata.

(5) -Boc-pipecolyl- (B and 5) -1-phenyl-7- (2-pyridyl) -4-heptyl ester (153). The ester 153 is obtained from 520 mg (1.93 mmol) alcohol 152, 442 mg (1.93 mmol) (S) -Boc-1-pipecolic acid, 370 mg (1.93 mmol) EDC and a catalytic amount of DMAP in 4 , 0 ml of methylene chloride and 4.0 ml of DMF as described above for the preparation of ester 122 in Example 1. Flash chromatography (eluting with hexane: ethyl acetate 3: 1) gave 740 mg of diastereoisomer ester 153 under the butter farm . ^{The 1} H NMR spectrum is consistent with the structure.

(R and S) -1-phenyl-7- (2-pyridyl) -4-2-eptyl- (S) -pipericolate (154). Amine 154 was prepared by treating 740 mg (1.54 mol) of ester 153 with 2.0 ml of trifluoroacetic acid in 5.0 ml of Ch-Ci ₂ as described above to obtain compound 123 in Example 1. 580 mg of the diastereoisomer amine 154 is obtained in the form of an oil. The 1 H NMR spectrum is consistent with the structure.

(R and 5) -1-phenyl-7- (2-pyridyl) -4-heptanol- (S) -1H-methyloxalylpiperate (155). To a solution of 48 mg (0.13 mmol) of amine 154 in 1.0 ml of CH ₂ CK at 0 ° C was added 33 pL (0.19 mmol) of N, N-diisopropylethylamine and 14 yl (0.15 mmol) of methyl oxalyl chloride. The resulting solution was warmed to room temperature and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with saturated NH ₄ Cl solution and brine, dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 25-30% ethyl acetate in hexane) afforded 49 mg of the deastereoisomeric amide 155 as a mixture of rotamers. ^{The 1} H NMR spectrum is consistent with the structure.

(R and S) - 1-phenyl-7- (2-pyridyl) -4-heptanol- (S) - N - [- (tert-butylglyoxyl) pipecolate (21). To a solution of amide 155 in 1.2 ml of THF at -78 < 0 > C was added dropwise tert-butyllithium until TLC indicated that the starting material was consumed. The reaction was quenched with saturated NH ₄ Cl solution and partitioned with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 30% ethyl acetate in hexane) afforded the diastereoisomeric amide 21 as a mixture of rotamers. ¹ H NMR (500 MHz, CDCI ₃ ): δ 8.50 (s), 7.57 (s), 7.20-7.05 (m), 5.23 (d),

5.18 (d), 4.56 (d), 4.44 (br d), 4.13 (d), 3.69 (br d), 3.37-3.28 (m), 3. 13-3.00 (m), 2.85-2.70 (m), 2.65-2.54 (m), 2.38-2.15 (m), 1.82-1.65m) , 1.56-1.44 ( _m ),

Example 8

Preparation of (R) and (S) -1- (3-phenylpropyl) -4-pyridin-2-yl-butyl ester of (S) -1- [2-oxo-2- (3,4,5-trimethoxyphenyl) acetyl ] piperidine-2-carboxylic acid (9) (E and 2) -3- (1,3-dioxan-2-yl) -1- (3-pyridyl) -1-propene (156). To a suspension of 9.9 g (22.4 mmol) of [2- (1,3-dioxan-2-yl) ethyl] triphenylphosphonium bromide (Aldrich Chemical Co) in 50 ml of THF at 0 ° C was added 14 ml (22 , 4 mmol) butyllithium (1.6 M in hexane) and the resulting red solution was stirred for 0.5 h at 0 ° C. 1.8 ml (18.7 mmol) were added to the solution.

3-Pyridinecarboxaldehyde (Aldrich Chemical Co). The reaction mixture was stirred for 1.5 hours at room temperature, then poured into water and partitioned with ether. The combined ether extracts were dried over MgSO ₄ and concentrated. Flash chromatography (eluting with hexane: ethyl acetate 2: 1) afforded 3.3 g of alkene 156 as a mixture of ogefin isomers. The 1 H NMR spectrum is consistent with the structure.

1- (1,3-Dioxan-2-yl) -3- (3-pyridyl) propane (157). A constant stream of hydrogen was purged through a solution of 3.2 g (16.7 mmol) of olefin 156 and 300 mg of 10% palladium-on-carbon over a period of 10 minutes. The reaction mixture was then filtered through celite and concentrated, whereby 2.8 g of acetal 157 were obtained as a colorless oil. ^{The 1} H NMR spectrum is consistent with the structure.

4- (3-Pyridyl) -1-oil aldehyde (158). A solution of 1.5 g (7.8 mmol) of acetal 157 in 10.0 ml of THF and 10.0 ml of 4N HCl was stirred overnight at room temperature and then neutralized by slow addition of solid NaHCO ₃ . The reaction mixture was extracted with ethyl acetate, dried over MgSO ₄ and concentrated to give 1.1 g of aldehyde 158. The ¹ H NMR spectrum was consistent with the structure.

(R and S) -1-phenyl-7- (3-pyridyl) -4-heptanol (159). Alcohol 159 was obtained from 1.1 g (7.4 mmol) of aldehyde 158 and 8.1 ml (8.1 mmol) of compound 120 in 3.0 ml of THF as described above in the preparation of alcohol 121 in Example 1. 1.9 g of the crude alcohol was obtained 159. Ή The NMR spectrum was consistent with the structure.

(S) -Boc-pipecolyl- (P and S) -1-phenyl-7- (3-pyridyl) -4-heptyl ester (160). The ester 160 is obtained from 1.65 g (6.12 mmol) of alcohol 159, 1.54 g (6.73 mmol) (S) -Boc-pipecolic acid, 1.29 g (6.73 mmol) of EDC and catalytically amount of DMAP in 8.0 ml of methylene chloride and 8.0 ml of DMF as described above to obtain the ester 122 in Example 1. Flash chromatography (eluting with hexane: ethyl acetate 2: 1) afforded 1.42 g of the diastereoisomeric ester 160 under the butter farm. ^{The 1} H NMR spectrum is consistent with the structure.

(R and S) -1-Srenyl-7- (3-pyridyl) -Scheptyl - ($) - pipecolate (161). Amine 161 was obtained by treating 1/2 g (2.95 mmol) of ester 160 with 2.0 ml of trifluoroacetic acid in 8.0 ml of CH ₂ Cl ₂ as described above to obtain compound 123 in Example 1. 1.02 g of the diastereoisomeric amine 161 are obtained under the butter farm. The 1 H NMR spectrum is consistent with the structure.

(R and S) -1-Phenyl-7- (3-pyridyl) -4-heptyl- (S) -N- (3,4,5-trimethoxyphenylglyoxyl) -piperate (9). Esther 9 was prepared from 995 mg (2.61 mmol) of amine 161, 645 mg (2.87 mmol) of acid 124 and 551 mg (2.87 mmol) of EDC in 6.0 ml of CH-C! ₂ as described above for the preparation of ester 3 in Example 1. Flash chromatography (eluting with acetone: hexane 3: 1) afforded 976 mg of the diastereoisomer amide 9 as a mixture of rotamers. ^{The 1} H NMR spectrum is consistent with the structure.

Example 9

Preparation of (R and 8) -1-phenyl-7- (3-pyridyl) -4-heptyl- (S) - N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate N-oxide (22) (R and 8) - 1-Phenyl-7- (3-pyridyl) -4-heptyl- (S) -N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate N-oxide (22). To a solution of 15 mg (0.02 mmol) of amide 9 in 2.0 ml of CH ₂ Cl ₂ at room temperature was added 9.3 (0.03 mmol) of 55% 3-chloroperoxybenzoic acid and the resulting solution was stirred. overnight at room temperature. . Flash chromatography (elution with 100% acetone) afforded 12.6 mg of N-oxide 22 as a mixture of rotamers. 1 H NMR (500 MHz, CDCl ₃ ): b 8.10 (t), 7,457.02 (t), 5.88 (d), 5.80 (d), 5.06-5.00 ( t), 4.95-4.89 (t), 4.61 (t), 4.31 (dd),

3.87 (s), 3.84 (s), 3.83 (s), 3.81 (s), 3.78 (s), 3.50 (br d), 3.27 (ddd). 3.12 (ddd), 3.00 (ddd), 2.67-2.49 (m), 2.32 (br d), 1.86-1.78 (m), 1.55-1, 50 (m), 1.39-1.22 (m).

Example Yu

Preparation of (R and 3) -1- <Phenyl-7-purinyl'-4-heptyl- (S) - N- (3,4,5-trimethoxyphenylglyoxyl) pipecolate (25)

4-Hydrochloride aldehyde (162). To a solution of 19.1 g (0.16 mol) of 4-chloro-1-butanol (Aldrich Chemical Co.) in 50 ml of CH ₂ Cl ₂ at 0 ° C was added 1.0 g of powder molecular sieve 4Ά and 38, 7 g (0.18 mol) of pyridinium dichromate and the resulting suspension was stirred for 45 min at 0 ° C. The reaction mixture was diluted with ether, filtered through celite and concentrated. The residue was distilled in vacuo (bp 45-55 ° C) to give 5.0 g of the aldehyde 162 as an oil. The NMR spectrum agrees with the structure.

(R and 3) -1-chloro-7-phenyl-4-heptal (163j. Alcohol 163 is obtained from 182 mg (1.7 mmol) of aldehyde 162 and 1.9 ml (1.9 mmol). from a compound

120 in 20.0 ml of THF as described by nc-'ope in the preparation of the alcohol.

121 in Example 1. Obtained 128 mg of alcohol 163 (flash chromatography in 100% methylene chloride). ^! The H NMR spectrum agrees with the structure.

(S) -Bocenylpecolyl-1R and 3) -1-chloro-7-phenyl-4-heptyl ester (164). The ester 164 is prepared from 128 mg (0.56 mmol) of alcohol 163, 156 mg (0.68 mmol) of (3) -Boc-pipecolic acid. 1380 mg (0.68 mmol) of EDC and a catalytic amount of 4-pyrrolidinopyridine in 2.0 ml as described above for the preparation of ester 122 in Example 1. After flash chromatography (eluting with ether: methylene chloride: hexane 1: 5: 14) 159 mg of the diastereoisomer ester 164 are obtained. The ¹ H NMR spectrum is consistent with the structure.

(3) -Boc-pipecolyl- (R and 3) -1-phenyl-7-purinyl-4-heptyl ester (165). To a solution of 34 mg (0.28 mmol) of purine in 3.0 ml of DMF at room temperature was added 8.4 mg (0.28 mmol) of solid NaH (80% in mineral oil) and the resulting solution was stirred at room temperature. 10 min. To the reaction mixture was added 62 mg (0.14 mmol) of ester 164 and 10 mg of sodium chloride. The mixture was stirred overnight at room temperature and then concentrated to dryness. The residue was dissolved in ethyl acetate, washed sequentially with water, saturated NaHCO ₃ solution and brine, then dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 15% NH ₄ OH: MeOH: CH ₂ Cl ₂ 5:10:85 in CH ₂ Cl ₂ ) gave 56 mg of the substituted purine 165 as an oil. Ή The NMR spectrum agrees with the structure.

(R and 3) -1-Phenyl-7-purinyl-4-heptyl- (S) -pipecolate hydrochloride salt (166). Through a solution of 53.7 mg (0.10 mmol) of ester 165 in 10 ml of ethyl acetate, purge dry HO for ϋ min at -20 ° C, then purge the reaction mixture with K ' _: . Concentration gave crude amine 166 as the hydrochloride salt. The NMR spectrum is in agreement with the structure.

(R and 5) -1-Phenyl-7-purinyl-4-heptyl - ((S) - N- (3,4,5-trimethoxyphenyl) glyoxyl) pipecolate (25). To a mixture of crude amine 166 as the hydrochloride salt and CH ₃ CN at room temperature were added 45 pL (0.26 mmol) Ν, diisopropylethylamine, 37 mg (0.15 mmol) of the acid 124 and 54 mg (0.12 mmol) The BOP reagent and the resulting mixture was stirred at room temperature for 2 days, then concentrated to dryness. The residue was washed with 75 ml of ethyl acetate and washed sequentially with water, 5% KHSO ₄ , saturated NaHCO ₃ solution and brine, then dried on MaSO ₄ and concentrated. Flash chromatography (eluting with MeOH: ether: methylene chloride 1: 4: 36) afforded 26.5 mg of the diastereoisomer amide 25 as a mixture of rotamers. Ή NMR (500 MHz, CDCI3): δ 9.11 (s), 8.95 (m), 8.09 (m), 7.36-7.05 (m), 5.31 (m) , 4.28 (m), 3.90 (m), 3.46 (br t), 3.20 (m), 2.58 (m), 2.28 (br d), 2.17-1 , 18 (m). R _f 0.1 (30% ether in methylene chloride).

Example 11

Preparation of (R and S) -4- [4-Morpholine-4-carbonyl) phenyl] -1- (3-phenyl propyl) butyl ester of (S) -1- [2-oxo-2- (3,4 , 5-trimethoxyphenyl) acetyl] piperidine-2 · carboxylic acid (44)

4-Formylbenzoic acid methyl ester (167). To a suspension of 9.6 g (63.5 mmol) of 4-carboxybenzaldehyde (Aldrich Chemical Co) in 100 ml of CH ₂ Cl ₂ at OX was added excess trimethylsilyldiazomethane and the resulting mixture was stirred for 1 hour at 0 ° C. The mixture was poured into saturated aqueous NaHCO ₃ and extracted three times with ethyl acetate. The combined organic extracts were dried over MgSO ₄ , filtered and concentrated to give 4.3 g of ester 167 as an oil. Ή The NMR spectrum agrees with the structure.

(E and 2) -4- [3- [1,3] -Dioxolan-2-yl-propenyl) -benzoic acid methyl ester (168). Olefin was obtained from 4.3 g (26.2 mmol) of aldehyde 167, 13.94 g [1- (1,3-dioxan-2-yl) ethyl] triphenylphosphonium bromide and 12.6 ml (32.0 mol) of n-BuLi in 75 ml of THF as described in the preparation of compound 156 in Example 8. Flash chromatography (eluting with 10% ethyl acetate in hexane) gave 3.27 g of olefin 168. 1 H NMR spectrum is in agreement with the structure.

4- [3- (1,3] -Dioxolan-2-yl-propyl) -benzoic acid methyl ester (169). Olefin 168 was hydrogenated on 328 mg of 10% Pd / C in 50 ml of EtOH as described for compound 157 in Example 8. Filtration and evaporation gave 2.85 g of compound 169 as an oil. The 1 H NMR spectrum is consistent with the structure.

[4- (3- (1,3] -Dioxan-2-yl-propyl) -phenyl] -methanol (170) To a solution of 2.85 g (11.4 mmol) of ester 169 in 25 ml of THF 4.4 ml (24.7 mmol) of diisobutylaluminum hydride are added at 0 ° C and the resulting mixture is stirred for 15 min at 0 ° C. The reaction is quenched with saturated potassium sodium tartrate solution and the mixture is extracted three times with ethyl acetate. The combined organic extracts were dried over MgSO ₄ , filtered and concentrated to give 2.58 g of crude alcohol 170 as an oil. The 1 H NMR spectrum was consistent with the structure.

2- [3- (4-tert-Butyldiphenyl silo yloxymethyl or phenyl) propyl] - [1,3] dioxolane (171). ). To a solution of 2.58 g (11.6 mmol) of alcohol 170 u

1.19 g (17.5 mmol) of imidazole in 50 ml of CH ₂ Cl - at 0'C were added 3.4 ml (13.1 mmol) of tert-butyl chlorodiphenyl silane and the resulting mixture was stirred for 1 hour at room temperature. The mixture was diluted with ethyl acetate and washed with 0.5 N HCl. The organic layer was dried over MgSO ₄ , filtered and concentrated. Flash chromatography (eluting with 5% ethyl acetate in hexane) afforded 5.5 g of compound 171. ^] H NMR spectrum consistent with structure.

4- (4-tert-Butyldiphenylsilylo k with ethyl phenyl] - methyl aldehyde (172) To a solution of 5.5 g (11.9) mmol of dioxolane 171 in 40 ml of THF at room temperature was added 40 ml. 4N HCl and the resulting solution was stirred for 1 hour The mixture was neutralized with solid K ₂ CO ₃ , extracted with ethyl acetate and concentrated The crude mixture was dissolved in 25 ml CH ₂ Cl ₂ to which 600 mg (8, 8 mmol) imidazole and 1.9 ml (7.3 mmol) tert-butyl chlorodiphenyl silane The resulting mixture was stirred overnight at room temperature and then poured into 0.5N HCl and extracted with ethyl acetate. The extracts were quenched on MgSO ₄ , filtered and concentrated, and flash chromatography (eluting with 8% ethyl acetate in hexane) gave 2.12 g of the aldehyde 172 as an oil. ¹ H NMR spectrum in agreement. with the structure.

1- (4-tert-Butyldiphenylsilyloxymethylphenyl) -7-phenyl-heptan-4-ol (173). Alcohol 173 was obtained from 2.-2 g (5.0 mmol) of aldehyde 172 and 9.0 ml (9 mmol) of compound 120 in ml of THF as described above in the preparation of alcohol 121 in Gsimer 1. After flash chromatography (eluting with 10% ethyl acetate in hexane; 3.3 g of the alcohol 173. was obtained ^. 1 H NMR spectrum was consistent with the structure.

(R and 3) -2- [4- (4-tert-Butyldiphenylsilyloxymethylphenyl) -1- (3-phenylpropyl) butyl] -ester, (8) -piperidine-1,2-dicarboxylic acid 1-tert-butyl ester (174). The ester 174 is obtained from 3.3 g (6.15 mmol) of alcohol 173, 1,? g (7, b mmol ', 8) -Boc-pipecolic acid, 1.4 g (7.3 mmol) of EDC and a catalytic amount of DMAP in 35 ml of methylene chloride as described above for the preparation of ester 122 in Example 1 Flash chromatography (eluting with 5% ethyl acetate in hexane) afforded 2.4 g of ester 174. The ¹ H NMR spectrum was consistent with the structure.

(R and S) -2- [4- (4-Hydroxymethyl-1-yl) -1- (3-phenylpropyl) butyl] -ester,

(S) -nperidine-1,2-dicarboxylic acid 1-tert-butyl ester (175). To a solution of 750 mg (1.0 mmol) of ester 174 in 10 ml of THF was added 1.1 ml (1.1 mmol) of tetrabutylammonium fluoride solution (1.0 M in THF) and the resulting mixture was stirred for 15 minutes at room temperature. The mixture was diluted with ethyl acetate, washed with 5% KHSO ₄ solution, dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 20% ethyl acetate in hexane) afforded 308 mg of the alcohol 175. ^The NMR spectrum was consistent with the structure.

(R and S) -2- [4- (4-Carboxyphenyl) -1- (3-phenylpropyl) butyl] -ester, (8) -piperidine-1,2-dicarboxylic acid 1-tert-butyl ester (176) . To a solution of 326 mg (0.64 mmol) of alcohol 175 in 3.0 ml of acetone was added 0.5 ml (1.27 mmol) of Jones reagent and the resulting mixture was stirred for 1 hour at room temperature and then stirred. filtered through a pad of celite and concentrated. Flash chromatography (eluting with 2% MeOH in CH ₂ Cl ₂ ) gave 155 mg of the -silane 176. The 1 H-NMR spectrum was consistent with the structure.

(R and S) -4- (4-Carboxyphenyl) -1-; 3-: oenylpropyl) butyl ester of (S) Liperidine-2-carboxylic acid trifluoroacetate (176). To a solution of 155 mg (0.3 mmol) of acid 176 is 3.0 ml of CH ₂ Cl) ₂ was added 500 µl of trifluoroacetic acid and the resulting solution was stirred for 3 hours at room temperature, after which the volatiles were removed in vacuo. The crude residue was suspended in 5.0 ml of dry benzene and then the volatiles were removed to give an anhydrous salt sample 177.

(R and S) -4- (4-Carboxyphenyl) -1- (3-phenyl propyl) butyl ester of (S) -1- [2-oxo-2- (3,4,5-trimethoxyphenyl) acetyl] ~ piperidine -2-carboxylic acid (178). To a suspension of 159 mg (0.3 mmol) of salt 177 in 2.5 ml of CH ₂ Cl ₂ at 0 ° C was added 110 µl (0.63 mmol) of N, N-diisopropylethylamine and then 40 µl (0, 31 mmol) chlorotrimethylsilane and the resulting mixture was stirred for 30 min at 0 ° C. 85 mg (0.44 mmol) of EDC and 106 mg (0.44 mmol) of acid 124 were added to this solution and the resulting mixture was stirred overnight at room temperature. . The mixture was diluted with ethyl acetate and washed with 0.5 N HCl, water and brine, then dried over MgSO ₄ and concentrated. Flash chromatography (eluting with 30% MeOH in methylene chloride) gave 97 mg of product 178 as a mixture of rotamers. ^{The 1} H NMR spectrum is consistent with the structure.

(R and 5) -4- [4-Morpholine-4-carbonyl) phenyl] -1- (3-phenylpropyl) butyl ester of (5) -1- [2-oxo-2- (3,4,5-trimethoxyphenyl) acetyl] piperidine-2carboxylic acid (44). To a solution of 11.2 mg (17 pmol) of acid 178 in 1.0 ml of CH ₂ Cl ₂ was added 4.1 mg (21.4 pmol) of EDC and 1.8 mg (20.7 mole) of morpholine and the resulting the solution was stirred overnight at room temperature. Flash chromatography (eluting with 20% MeOH in methylene chloride) yielded 7.6 mg of amide 44 as a mixture of rotamers. H NMR (500 MHz, CDCI ₃ ): δ 7.32 (d), 7.30 (d), 7.26 (s), 7.21-7.08 (m),

5.33 (m), 5.01 (m), 4.92 (m), 3.92 (s), 3.89 (s), 3.88 (s), 3.87 (s), 3 , 86 (s), 3.85 (s), 3.81-3.53 (m), 3.42 (br d), 3.29-3.21 (m), 3.05 (m), 2.61 (m), 2.42 (dd), 2.31 (d), 2.12 (m), 1.83 (m), 1.73-1.42 (m), 1.42- 1.20 (m).

OM ·

Example 12 - NMR data

We have also obtained other compounds of formula (I) by substantially analogous methods to those described in Examples 1-11 above, as well as those illustrated in Schemes 1-3. The NMR spectral data for these compounds are summarized below. The numbering of the compounds corresponds to that in Table 1.

Compound 2: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.42-8.33 (m), 7.51 (d), 7.42 (d ),

7.38 (s), 7.31 (d), 7.29-7.05 (m), 5.01 (br s), 4.8 (m), 4.71 (m), 4.62 (m), 3.92-

3.83 (m), 3.81 (d), 3.60-3.51 (m), 3.50-3.45 (m), 2.65-2.51 (m), 2.50 -2.39 (m),

2.38-2.22 (m), 2.05 (m), 1.95 (m), 1.81-1.68 (mi, 1.67-1.49 (m), 1.48-1, 31 (m),

1.22 (s).

Compound 5 : ^! H NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers); 5 7.39-6.80 (t), 6.75 (d), 5.47 (t),

4.55 (t), 4.45 (t), 3.95-3.78 (t), 3.49-3.40 (t), 3.22-3.11 (t), 2.49 -2.38 (t),

1,88-1,6? (t), 1.61-1.42 (t), 1.37-1.14 (t).

Compound 6: 1 H NMR (500 MHz, CDCl 3), (mixture of diastereoisomers, mixture of rotamers): δ 7.36-7.19 (m), 7.18-7.02 (m), 5 , 77 (t), 5.65 (m), 5.39 (m), 4.60-4.52 (m), 4.35 (m), 3.93-3.82 (m), 3 , 71-3.63 (m), 3.48-3.42 (m), 3.41-3.34 (m), 3.28-3.19 (m), 3.12-3.07 (m), 2.65-2.58 (m), 2.57-

2.48 (m), 2.42-2.31 (m), 2.02-1.94 (m), 1.91-1.21 (m), 1.11-1.02 (m) .

Compound 10: ¹ H NMR (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): δ 7.35-5.98 (m), 5.35 (d), 5.3-5 , 14 (m),

4.52 (br d), 4.24 (br s), 3.97-3.87 (m), 3.49 (t), 3.12 (q), 3.00-2.56 (m ), 2.46 (t),

2.32 (d), 2.18 (d), 2.11 (d), 1.93 (d), 1.83-1.56 (m), 1.55-1.38 (m), 1.32-1.18 (m), 0.94-0.72 (m).

όύ

Compound 12: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.37 (s), 7.31-7.06 (m), 6.98 (d ),

5.39 (dd), 5.09-5.00 (m), 4.99-4.93 (m), 4.73 (d), 4.38 (m), 3.98-3.86 (m) ), 3.91 (s), 3.50 (d), 3.34-3.24 (m), 3.09 (t), 2.73-2.16 (m), 2.02-1 , 24 (m).

Compound 13: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.38 (s), 7.29-7.21 (m), 7.20-7 , 03 (m), 6.99 (d), 6.88 (d), 6.82-6.73 (m), 5.40-5.32 (m), 5.04-4.98 ( m), 4.97-4.91 (m), 4.61 (d), 4.37 (d), 3.93-3.83 (m), 3.81-3.74 (m), 3. 53-3.47 (br d), 3.32-3.22 (m), 3.11-3.04 (m), 2.65-2.12 (m), 1.97-1.21 (m).

Compound 14: H NMR (500 MHz, CDCl3), (mixture of diastereoisomers, mixture of rotamers): δ 8.04 (d), 7.97 (t), 7.59-7.48 (m), 7.47-7.41 (m), 7.31-7.22 (m), 7.21-7.02 (m), 6.98-6.91 (m), 6.82-6, 76 (m), 5, -3-

5.38 (m), 5.12-5.03 (m), 4.93 (m), 4.65-4.60 (m). 4.36 (m), 3.39 (m), 3.53-3 / 8 (m), 3.23 (q), 3.11-2.99 (m), 2.68-2.29 (m ), 2.19 (t), 1.98-1.31 (m).

Compound 15: Ή NMR spectrum (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.05-7.92 (m), 7.78 (d), 7.47-7, 03 (t), 6.42 (br s), 5.33 (d), 5.01 (t), 4.94 (t), 4.59 (br d), 4.32-4.14 (t) , 4,084.00 (t), 3.97-3.84 (t), 3.77-3.68 (t), 3.45 (br d), 3.17-3.08 (t), 2 , 97 (t), 2.60 (t), 2.48 (t), 2.35-2.21 (m), 2.11 (d), 2.05-1.10 (m), 0 , 91-0.79 (m).

Compound 17: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.38-6.92 (m), 6.82-6.71 (m), 5 , 38-

5.29 (m), 5.06-4.85 (m), 4.60 (d), 4.31 (d), 3.94-3.81 (m), 3.79-3.70 (m), 3,513.41 (m), 3.23 (br t), 3.06 (t), 2.62-2.22 (m), 2.15 (d), 1.82-1, 29 (m).

Compound 18: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.55-8.38 (m), 8.08-8.00 (m), 7 , 98 (d), 7.68 (t), 7.59 (t), 7.50-7.45 (m), 7.45-7.41 (m), 7.29-7.25 ( m), 7.25-7.08 H,

5.40 (m), 5.11 (m), 4.93 (m), 4.61 (br d), 4.38 (m), 3.61 (m), 3.59-3.46 (m ),

3.26-3.15 (m), 3.08-2.96 (m), 2.70-2.61 (m), 2.58-2.49 (m), 2.38 (br d ), 2.19 (br d), 1.83-1.78 (m), 1.78-1.59 (m), 1.56-1.43 (m), 1.41-1.24 (m).

Compound 19: ¹ H NMR (500 MHz, CDClj), (mixture of diastereomers, mixture of rotamers): δ 8,52-8,49 (m), 8,04 (d), 7,96 (d) , 7.64 (t), 7.61-7.57 (m), 7.52 (t), 7.46-7.41 (m), 7.26-7.22 (m), 7, 17 (t), 7.12-7.08 (m), 5.41 (d), 5.12 (m), 4.93 (m), 4.61 (br d), 4.38 (d) ), 3,893.83 (m), 3.67-3.61 (m), 3.53-3.48 (m), 3.28-3.19 (m), 3.06-3.00 ( m), 2.83 (br t), 2.72 (br t), 2.65 (br t), 2.52 (br t), 2.48 (br d), 2.21 (br d) , 1.89-1.73 (m), 1.73-1.70 (m), 1.70-1.48 (m), 1.48-1.33 (m).

Compound 20: Ή NMR spectrum (500 MHz, CDCl3), (mixture of diastereoisomers, mixture of rotamers): δ 8.50 (d), 7.61 (dd), 7.28-7.25 (m), 7.21-7.16 (m), 7.12 (dd), 5.38 (br d), 5.09-5.02 (m), 4.93-4.90 (m), 4. 62 (br d),

4.34 (m), 3.94 (s), 3.92 (s), 3.91 (s), 3.90 (s), 3.89 (s), 3.49 (br ddd), 3.28 (ddd), 3.09 (dd), 2.83 (t), 2.74 (m), 2.63 (br d), 2.49 (dd), 2.36 (br d) , 2.19 (br d), 1.86-1.70 (m), 1.70-1.62 (m), 1.59-1.52 (m), 1.48-1.23 ( m).

Compound 23: ¹ H NMR (500 MHz, CDCl 3), (mixture or diastereoisomers, mixture of rotamers): δ 8.30 (d), 8.28 (d), 7.79 (d), 7.34 (s), 7.31-7.00 (m), 6.43 (s), 5.33 (d), 5.06 (d), 4.94 (m), 4.59 (d), 4.42-4.10 (m), 4.04 (s), 3.96 (s), 3.94 (s), 3.92 (s), 3.81 (s), 3.77 ( s), 3.84 (d), 3.27 (dt), 3.05 (dt),

2.67-2.47 (m), 2.32 (d), 2.14 (d), 2.03-1.22 (m), 0.94-0.81 (m).

Compound 26: 1 H NMR (500 MHz, CDCl 3), (mixture of diastereoisomers, mixture of rotamers): δ 7.32 (d), 7.27-6.99 (m), 5.34-5, 28 (m), 5.00 (br s), 4.61 (d), 4.30 (d), 3.92-3.81 (m), 3.02 (t), 2.4-2 , 48 (m), 2.47-

2.39 (m), 2.34-2.22 (m), 2.14 (d), 1.82-1.14 (m).

Compound 27: Ή NMR (500 MHz, CDCl3), (diastereoisomer mixture, rotamer mixture): δ 8.46-8.38 (m), 7.68-7.50 (m), 7.49 -

7.30 (m), 7.29-7.08 (m), 5.48 (m), 5.16-5.02 (m), 4.98-4.90 (m), 4.60 (d), 4.32 (d), 3.51-3.42 (m), 3.26-3.12 (m), 3.11-2.98 (m), 2.65-2.42 ( m), 2.32 (br d), 2.14 (br d), 1.83-1.22 (m).

Compound 28 : ^! H NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.45-8.32 (m), 7.62-7.53 (m), 7.527.43 (m ), 7.42-7.05 (m), 6.09-5.98 (m), 5.44-5.25 (m), 5.09 (br s), 4.92 (br s),

4.64-4.51 (m), 4.31 (d), 3.50-3.41 (m), 3.24-3.12 (m), 3.07-2.94 (m), 2 , 68-2.45 (m), 2.32 (br d), 2.14 (br d), 1.83-1.26 (n).

Compound 29: ¹ H NMR spectrum> 500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): c 8.44-8.37 (m), 7.58-7.51 (m), 7.507 , 08 (t), 5.35 (br t), 5.10 (br s), 4.93 (br s), 4.68-4.54 (m), 4.32 (d), 3. 51-3.42 (m), 3.25-3.12 (m), 3.00 (q), 2.69-2.45 (-.), 2.38-2.29 (m), 2.14 (br d), 1.82-1.20 (m).

Compound 30: Ή NMR 500MHz, CDCi _3), (mixture of diastereomers, mixture of rotamers. With 7,35 (s), 7,29-7,20 (m ), 7,19-7,02 (m), 6.89 (m), 6.77 (m), 5.34 (d), 5.03 (- 4.91 (m), 4.61 (d). 4.33 (d), 3 , 95-3.88 (m), 3.48 (d), 3.31-3.21 (m), 3.05 (br t), 2.87-2.43 (m), 2.32 (br d), 2.18 (br d),

1.87- 1.21 (m).

Compound 31 : ^! H NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers ;: ό 8,00 (br s), 7,34 (br s), 7,31-7,02 (m), 5.34 (br s), 5.31 (br s), 5.03 (br s) 4.92 (br d), 4.61 (br d), 4.33 (br s), 3, 96-3.84 (m), 3.48 (br d), 3.24 (br s), 2.76-2.42 (m), 2.32 (br d), 2.15 (m),

1.87- 1.20 (m).

Compound 32: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers: 5 7.38 (d), 7.30-7.08 (m), 7.07-7 , 03 (d), 5.35-5.31 (m), 4.98 (m), 4.88 (m), 4.59 (m), 4.31 (m), 3.97-3.86 (m), 3.46 (hill), 3.29-3.18 (m), 3.04 (m), 2.65-2 / 2 (m), 2.35-2.22 (m) , 1.83-1.14 (m), 1.10 (m).

ο?

Compound 33: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.38 (d), 7.32-7.24 (m), 7.24 (d ),

7.21 (d), 7.01 (s), 7.00 (s), 6.02-5.99 (m), 5.92-5.88 (m), 5.38 (d), 5.36 (d), 4.70 (AB-q), 4.69 (AB-q), 4.64 (AB-q), 4.32 (br d), 3.91 (s), 3 , 89 (s), 3.88 (s), 3.74 (s), 3.73 (s), 3.48 (br ddd), 3.36 (br d), 3.20 (ddd), 3. 06-2.97 (m), 2.62 (t), 2.58 (t), 2.38 (br d), 2.21 (br d), 2.08-2.04 (m), 1.90-1.74 (m), 1.73-1.46 (m), 1.38-

1.33 (m), 1.24 (t).

Compound 34: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): 3 7.33 (s), 7.30 (d), 7.29 (s), 7. 28-7.20 (m), 7.18-7.11 (m), 6.95-6.90 (m), 6.83 (cj, 6.82 (d), 6.31-6, 28 (m), 6.02-5.91 (m), 5.43-5.40 (m), 5.21 (dd), 4.53 (d), 3.91 (s), 3.89 ( s), 3.86 (s), 3.85 (s), 3.84 (s), 3.75 (s), 3.71 ($), 3.45 (br ddd), 3.40 ( br ddd), 3.28 (ddd), 3.15 (ddd), 3.02 (ddd) 2.62 (dd) 2.40 (br d) 1.94-1.89 m), 1.87-1.67 (m), 1.65-1.50 (m).

Compound 35: H NMR spectrum (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers ;: a 7.34-7.29 (m), 7.28-7.11 (m), 7. 10-

6.93 (t), 5.35-5.28 (t), 5.09-4.98 (t), 490 (t), 4.64-4.44 (t), 4.30 (t) ), 3,953.81 (t), 3.46 (br t), 3.31-3.19 (t), 3.0; (t), 2.66-2.38 (t), 2.34-2.25 (t), 2.16 (t), 1.85-1.19 (t).

Compound 36: Ή NMR (500 MHz, CDCl 3, (mixture of diastereoisomers, mixture of rotamers / δ 7.93-7.81 (m), 7.78 (s), 7.41-7.01 (m ), 5.32 (br s), 5.02 (br s), 4.90 (m), 4.58 (d), 4.31 (br s), 3.95-3.80 (m), 3 , 45 (d), 3.22 (t), 3.05 (m), 2.72-2.48 (m), 2.47 (d), 1.83-1.43 (m). -1.18 (m).

Compound 37: H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers: δ 7.38 (s), 7.30 (s), 7.30-7.02 (pt) , 7.01 (s), 5.83-5.80 (m), 5.58 (dd), 5.62 (dd), 5.38 (d), 5.36 (d), 4.66 (s) ), 4.65 (AB-q), 4.54 (s), 4.32 (br d), 4.28 (br c), 3.90 (s), 3.88 (s), 3. 86 (s) 3.85 (s),

3.84 (s), 3.78 (s), 3.76 (s), 3.43 (br ddd), 3.39 (br ddd), 3.24 (ddd), 3.12 (ddd) , 3.06 (ddd), 2.97 (ddd), 2.62 (t), 2.57 (t), 2.48 (br d, 2.24 (br d), 2.01-1, 94 (m), o4

1.89-1.73 (m), 1.72-1.65 (m), 1.65-1.58 (m), 1.52-1.49 (m), 1.40-1, 33 (m), 1,121.08 (m).

Compound 40: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.36 (s), 7.29-7.19 (m), 7.18-7 , 06 (m), 6.89 (m), 6.75 (s), 5.32 (br s), 4.95 (t), 3.95-3.84 (m), 3.46 ( br d), 3.22 (m), 2.82 (t), 2.61 (t), 2.30 (m), 1.82-1.19 (m).

Compound 41: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.37 (d). 7.29-7.08 (m), 7.04 (d),

5.34 (m), 4.97 (m), 4.61 (d), 4.33 (m), 3.96-3.88 (t), 3.86 (d), 3.48 ( d) 3.25 (m), 3.09 (m) 2.65-2.52 (m) 2.48 (m) 2.32 (d) 2.18 (d) 1.86 -1.49 (m), 1.48-1.15 (m).

Compound 42: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.34 (d), 7.2 (m), 7.13 (m), 7, 0-7.1 (m), 5.37 (m), 5.32 (m), 5.22 (dd), 5.12 (dd), 5.0 (m), 4.89 (bm), 4 , 57 (bd), 4.30 (bm), 3.95-3.80 (m), 3.45 (bd), 3.40 (m), 3.32 (m), 3.22 (dt) ), 3.05 (bm), 2.60 (m), 2.52 (bm), 2.44 (m), 2.30 (m) _r 2.15 (bm), 1.75 (m) , 1.60 (m). 1.54 (m), 1.45-

1.20 (bm).

Compound 43 : ^! H NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.36-7.30 (m), 7.29-7.20 (m), 7.197.04 (m ), 5.34 (m), 5.01 (br s), 4.91 (m), 4.59 (d), 4.31 (br s), 3.95-3.86 (m), 3.47 (br d), 3.25 (br t), 3.14-2.90 (m), 2.68-2.52 (m), 2.45 (t), 2.32 (d ), 2.18 (d), 1.35-1.46 (m), 1.45-, 18 (m).

Compound 45: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.35 (d), 7.25 (m), 7.15 (m), 7. 10 (d), 7.05 (d), 5.87 (m), 5.38 (bd), 5.34 (m), 5.22 (dd), 5.14 (dd), 4.95 (bm), 4.88 (bm), 4.58 (bd), 4.32 (m), 3.95-3.82 (m), 3.45 (bd), 3.40 (t), 3.25 (m), 3.05 (bm),

2.60 (bm), 2.44 (m), 2.34 (bd), 2.18 (bd), 1.78 (m), 1.70-1.48 (m), 1.45- 1.20 (m).

Compound 46: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.32 (s), 7.25 (m), 7.16 (m), 7. 10 9t),

5.85 (m), 5.50 (dt), 5.38 (dd), 5.25 (dd), 5.18 (d), 4.58 (bm), 4.35 (bm), 4 , 15 (s),

4.06 (d), 4.02 (d), 3.95-3.85 (m), 3.46 (bd), 3.25 (m), 3.08 (bt), 2.98 ( bt), 2.65 (t), 2.58 (t), 2.53 (t), 2.35 (bt), 2.20 (bd), 1.88-1.70 (m), 1 , 70-1.50 (m), 1.42-

1.20 (m).

Compound 47: Ή NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.44 (d), 7.42-7.06 (m), 5.45-5, 30 (m), 5.12-4.91 (m), 4.03-3.83 m), 3.82-3.19 (m), 2.72-2.26 (m), 1. 91-1.22 (m).

Compound 48: Ή NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.34 (d), 7.25 (m), 7.20 (d), 7.15 (m), 7.10 (d), 7.05 (d), 5.88 (m), 5.32 (bt), 5.24 (dd), 5.14 (dd), 4.96 ( m), 4.86 (m), 4.58 (bd), 4.30 (bm), 3.95-3.85 (m), 3.45 (bd), 3.38 (t), 3 , 32 (t), 3.25 (m),

Compound 49: 1 H NMR (500 MHz, CDCl 3) (mixture of diastereoisomers, mixture of rotamers): 7.42-7.28 (m), 6.61-6.57 (m), 6.51 -

4.94 (dd), 4.60-4.53 (br d),

4.38-4.35 (t), 3.95-3.80 (t), 3.74 (s),

3.50-3.38 (br dd), 3.31-3.22 (ddd), 3.22-3.15 (ddd), 3.08-2.96 (m), 2.4-24 , 32 (No dd), 1.85-

1.73 (m), 1.75-1.48 (m), 1.56-1.54 (d), 1.48-1.15 (m).

Compound 50: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): 0 7.34 (d), 7.24 (m), 7.15 (m), 7. 10 9d), 7.04 (d), 5.85 (m), 5.32 (m), 5.22 (dd), 5.15 (m), 5.00 (m), 4.58 ( bd), 4.30 (bs), 3.95-3.74 (m), 3.44 (m), 3.25 (bt), 3.04 (bm), 2.62 (m), 2.45 (t), 2.30 (bd),

2.18 (bd), 1.88 (m), 1.78 (m), 1.72-1.46 (m), 1.45-1.22 (m).

Compound 51: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.34 (s), 7.25 (m), 7.20 (d), 7. 14 (m),

7.10 (d), 7.06 (d), 5.87 (m), 5.78 (dt), 5.68 (m), 5.60-5.45 (m), 5.35 ( d), 5.24 (m), 5.15 (d), 4.58 (bd), 3.96-3.85 (m), 3.45 (m), 3.24 (m), 3 , 04 (m), 2.62 (m,

2.56 (t), 2.49 (dt), 2.34 (dt), 2.18 (bm), 1.82-1.48 (m), 1.40-1.24 (m).

Compound 52: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.40-7.03 (m), 5.38-5.28 (m), 5 , 02 (br s), 4.90 (m), 4.60 (d), 4.32 (br s), 3.99-3.87 (m), 3.86-3.31 (m) , 3.30-3.21 (No

t), 3.11-3.02 (brq), 2.69-2.50 (m), 2.47 (m), 2.32 (d), 2.14 (d), 1.89- 1.48 (m),

1.47-1.21 (m).

Compound 53: ^f H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.40 (d), 7.35 (d), 7.30 (d), 7. 28 (s),

6.60 (d), 6.55 (d), 6.52 (t), 6.49 (t), 5.86 (q), 5.78 (q), 5.42 (d), 5 , 08 (s), 4.64 (bd), 4.35 (m), 3.98-3.88 (m), 3.46 (bd), 3.21 (dt), 3.05 (dt), 2.36 (bd), 2.18 (bd), 1.80 (m), 1.74 (bd), 1.64 (s), 1.56 (d), 1.55-1.48 ( m), 1.40 (d), 1.30-1.15 (m).

Compound 54 : ^! H NMR (500 MHz, CDCi _3), (mixture of diastereomers, mixture of rotamers): δ 8.52 (m), 7,82-7,71 (m), 7,70-7,62 (m), 7.55-7.42 (m), 7.38-7.01 (m), 5.36-5.29 (m), 5.01 (m), 4.90 (m), 4.79 -4.67 (m), 4.59 (d), 4.39-4.11 (m), 3.96-3.73 (m), 3.44 (d), 3.22 (t) , 3.09-3.00 (br c;), 2.72-2.41 (m), 2.30 (d), 2.14 (d), 1.86-1.43 (m), 1. 42-1.02 (m), 0.98-0.73 (m).

Compound 55: Ή NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.38 (d), 7.33 (d), 7.29-7.02 (m) , 5.32 (m), 5.01 (m), 4.90 (m), 4.59 (m), 4.30 (m). 4.08-3.51 (m), 3.46 (d), 3.29-

3.18 (m), 3.11-2.98 (br q), 2.81-2.32 (mJ, 2.30 (d), 2.14 (d), 1.84-1.19 (m).

Compound 56: H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): 0 7.39-7.30 (gi), 7.27-7.20 (br s), 1.207, 15 (br t), 7.14-7.06 (br d), 5.81-5.78 (br t), 5.77-5.72 (br t), 5.34-5.30 (br. br d), 5.28 (s), 4.60-4.55 (br d), 5.33 (br s), 3.91 (s), 3.88 (s), 3.80 (br s), 3.79-3.48 (m), 3.47-3.30 (br d), 3.28-3.20 (br t), 3.01-2.94 (br t), 2.66-2.60 (t), 2.59-2.54 (t), 2.42-2.35 (br d), 2.25-2.19 (br d), 2.04- 1.93 (m), 1.89-1.73 (m), 1.72-1.65 (m), 1.64-1.57 (m), 1.54 (br s), 1. 39-1.25 (m), 1.20 (br s).

Compound 57 : ^! H NMR (500 MHz, CDCh), (mixture of diastereoisomers, mixture of rotamers): δ 7.32 (d), 7.31-7.01 (m), 5.31 (m>, 5.00) (m), 4.90 (m), 4.59 (m), 4.30 m), 3.93-3.83 (m), 3.82-3.63 (m), 3.49- 3.38 (m), 3.22 (t), 3.10-2.98 (t), 2.68-2.21 (m), 2.12 (m), 1.82-1.21 (m).

Compound 58: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.33-7.01 (m), 5.31 (m), 4.99 (m ), 4.89 (t), 4.59 (d), 4.29 (t), 3.92-3.84 (t), 3.83-3.64 (t), 3.55-3 , 28 (t), 3.22 (t), 3.04 (t), 2.63-2.22 (t), 2.14 (d), 1.81-1.21 (t).

Compound 59: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 7.71-7.52 (m), 7.42 (m), 7.39-7 , 04 (m), 6.72-6.59 (m), 5.32 (m), 5.22 (m), 5.11 (m), 5.01 (m), 4.99-4 , 90 (m), 4.69-

4.52 (m), 4.39-4.26 (m), 3.99-3.79 (m), 3.46 (t), 3.22 (t), 3.11-2.94 (m), 2.72-

2.40 (m), 2.29 (t), 2.20-2.11 (m), 1.88-1.18 (m), 0.89 (m).

Compound 60: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): 3 8.53 (m), 7.80 (m), 7.72-7.53 (m ).

7.39-7.03 (t), 5.36-5.28 (dd), 5.12-4.98 (t). 4.92 (t), 4.79-4.52 (t), 4.31 (t), 3.98-3.81 (t), 3.45 (t), 3.31-3.19 (br q), 3.11-3.00 (t), 2.72-2.43 (t), 2.31 'f), 2.20-2.11 (t), 1.88-1.22 (t).

Compound 61: Ή NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.45 (br s), 7.60-7.49 (m), 7.38-7 , 21 (m), 5.38-5.31 (m), 5.03-4.98 (m), 3.99-3.38 (m), 3.50 (br d), 3.29 (q), 2.65 (m), 2.38-2.31 (m), 1.88-1.13 (m), 0.92-0.74 (m).

Compound 62: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.65-8.55 (m), 7.40-7.32 (m), 7.006 , 80 (m), 5.78-5.74 (m), 5.71-5.62 (m), 5.89-5.85 (br d), 5.84-5.80 (br d) ), 5,215.13 (m), 5.10-5.03 (m), 4.81-4.77 (dd), 3.94-3.87 (m), 3.80 (s), 3 , 79 (s), 3.72 (s), 3.46-3.38 (br dd), 3.28-3.14 (m), 2.83-2.66 (m), 2.58-2 , 48 (m), 2.48-2.28 (m), 1.18-1.32 (m).

Compound 63: 1 H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.62 (d), 8.61-8.58 (m), 7.64 (dd ), 7.59 (dd), 7.32-7.24 (m), 7.12 (d), 6.92 (dd), 6.89-6.83 (m), 6.82 (d) ), 6.79 (d),

6.74 (d), 5.48 (d), 5.07 (d), 4.60 (m), 4.44 (br dd), 3.91 (s), 3.90 (s), 3.86 (s),

3.84 (s), 3.83 (s), 3.78 (s), 3.44 (br d), 3.18 (ddd), 2.92 (ddd), 2.40 (br t) , 2.32 (br t), 1.89-1.70 (m), 1.62-1.48 (m).

Compound 64: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): is 8.59 (d), 8.58 (d), 7.32-7.04 (m ), 6.99-6.80 (m), 5.62 (dd), 5.61 (dd), 5.38 (dd), 5.06 (s), 5.02 (d), 4. 99 (d), 4.53 (m), 4.36 (m), 3.91 (s), 3.90 (s), 3.89 (s), 3.88 (s), 3.84 (s), 3.69 (s), 3.61 (s),

3.46 (br d), 3.41 (br d), 3.24 (dd), 3.12 (dd), 2.62 (t), 2.58 (t), 2.34 (br t) ), 1,991.92 (m), 1.86-1.42 (m).

Compound 66: ¹ H NMR (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): c 8.56-8.51 (m), 7.35-7.28 (m), 7 , 27-

7.22 (t), 7.14 (s), 7.07 (s), 6.93-6.88 (t), 6.87-6.80 (t), 6.79-6.71 (t ), 6,65-

6.62 m, 5.81 (q), 5.71 (q), 5.32-5.27 (m). 5.20-4.98 (t), 4.57-4.47 (t), 4.28-

4.23 (t), 3.92-3.70 (t), 3.40 (br d), 3.20 (br d ;, 3.11 (ddd), 3.00-2.89 (m), 2.33 (d), 2.26 (d), 2.20 (d), 2.07 (d), 1.80-1.57 (m), 1.56-1.25 (m), 1.24-1.17 (m), 1.13-1.00 (m).

Compound 67: ¹ H NMR (500 MHz, CDCl 3, (mixture of diastereoisomers, mixture of rotamers): c 8.63-8.54 (m), 8.53-8.44 (m), 7.38 -

7.11 (m), 7.10-6.99 (m), 6.78 (d), 6.72 (dd), 6.63 (dd), 6.53 (d), 6.44 ( d), 6.14 (dd), 6.08 (dd), 6.00 (dd), 5.88 (dd), 5.39 (d), 5.31 (d), 5.23-4 , 95 (m), 4.61-4.50 (m), 4.32-4.29 (m), 3.91 (s), 3.90 (s), 3.38-3.74 ( m), 3.71 (s), 3.64-3.58 (m), 3.47-3.38 (m), 3.37-3.32 (m), 3.24 (ddd), 3.13 (ddd), 3.07 (ddd), 2.94 (ddd), 2.62-2.45 (m), 2.38-2.29 (m), 2.20-2.11 (m), 2.00-1.88 (m), 1.87-1.40 (m), 1.391.08 (m).

Compound 68: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.61 (d), 7.38 (d), 7.31 (s), 7.28 -7.22 (m), 7.14 (dd), 7.10 (d), 7.04 (d), 6.83 (d), 5.23 (dd), 5.14 (dd), 5.36 (d), 5.11 (br s), 4.58 (m), 4.31 (m), 3.91 (s), 3.90 (s), 3.89 (s), 3.88 (s), 3.82-3.79 (m),

3.78-3.64 (m), 3.51-3.44 (m), 3.40 (br d), 3.26-3.10 (m), 2.63 (dd), 2. 32 (br d), 2.00-1.92 (m), 1.88-1.40 (m), 1.08-1.00 (m).

Compound 69: ¹ H NMR (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): δ 8.60-8.57 (m), 8.56-8.53 (m), 7 , 38-

7.35 (t), 7.32-7.17 (t), 6.53 (s), 6.52 (s), 5.83 (q), 5.76 (q), 5.38- 5.32 (m), 5.17-5.05 (m), 4.67-4.60 (m), 4.30-4.28 (m ;, 4.13-4.08 (m) , 3.96-3.82 (m), 3.80 (s), 3.45 (br d), 3.28 (ddd), 2.97 (ddd), 2, / 7-2.72 ( m), 2.53-2.43 (m), 2.36-2.22 (m), 2.15-1.92 (m), 1.86-0.79 (m).

Compound 70: ¹ H NMR (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): 1 8.59-8.43 (m), 7.38-6.98 (m), 6 , 65 (s). 6.57 (s), 6.53 (t), 6.43 (t), 5.88-5.84 (t), 5.68-5.64 (t), 5.63-5.59 (t),

5.58-5.54 (t), 5.35-5.28 (t), 5.15-5.00 (t, 4.99 (d), 4.92 (d), 4.58 ( d), 4.51 (d),

4.33 (d), 4.26 (d), 3.89 (s), 3.8? (s), 3.83 .s), 3.19 (s), 3.72 (s), 3.65 (s), 3,453.37 (m), 3.21 (ddd), 3.10 (ddd) , 2.95-2.8 2 (m), 2.62-2.42 (m), 2.28 (d), 2.21 (d), 1.92-1.26 (m), 1.17 -1.12 (m), 1.11-1.0 '(m).

Compound 71: Ή NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers):: 8.64 (d), 7.35 (d), 7.28 (s), 6.60 (d), 6.55 (d), 6.52 (t), 6.49 (1), 5.86 (q), 5.78 (p), 5.42 (d), 5.08 ( s), 4.64 (bd), 4.35 (m), 3.98-3.88 (m), 3.46 (bd), 3.21 (dt), 3.35 (dt), 2 , 36 (bd), 2.18 (bd), 1.80 (m),

1.74 (bd), 1.64 (s), 1.56 (d), 1.55-1.48 (m). 1.40 (d), 1.30-1.15 (m).

Compound 72: ¹ H NMR. 500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): ό 8,62 (d), 7,35 (d), 7,28 (s), 6,60 (d), 6.50 (d), 6.45 (t), 6.42 (t), 5.85 (q), 5.73 (q), 5.40 (d), 5.10 ( d), 5.04 (d), 4.58 (bd), 4.38 (m), 3.92 (s), 3.88 (s), 3.82 (s), 3.72 (s) ), 3.50 (bd), 3.30 (dt), 3.01 (dt), 2.40 (bd), 2.30 (bd), 1.85 (m), 1.64 (os) , 1.56 (d), 1.48 (d), 1.45-1.35 (m).

Compound 73: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): ό 8,65-8,55 (br d), 7,42-7,32 (br dd) , 7.28 (s), 7.20 (s), 6.55-6.50 (m), 5.87-5.72 (m), 5.39-5.32 (m), 5. 17-5.05 (m),

Ό

4.64-4.58 (br d), 4.58-4.53 (br d), 4.36-4.34 (br d), 4.29-4.25 (br d), 3, 96-3.71 (m), 3.48-3.40 (m), 3.30-3.23 (ddd), 3.22-3.13 (ddd), 2.37-2.17 ( m), 1.86-1.50 (m), 1.52-1.58 (d).

Compound 74: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.62-8.58 (d), 8.57-8.51 (d), 7, 38-7.35 (d), 7.33-7.28 (m), 7.27 (s), 7.18 (s), 6.61 (s), 6.59 (s), 5. 65-5.60 (t), 5.55-5.50 (t), 5.40-5.36 (d), 5.18-5.05 (m), 4.67-4.63 ( br d), 4.33-4.30 (d), 3.96 (s), 3.93 (s), 3.92 (s), 3.87 (s), 3.50-3.43 (br d), 3.25-3.16 (dt), 3.05-2.97 (dt), 2.32-2.28 (br d), 2.14-2.08 (br d) , 1.95-1.85 (m), 1.84-1.64 (m), 1.63-1.56 (br d), 1.55-1.42 (m), 1.35- 1.23 (m), 1.22-1.12 (m), 0.92-0.83 (t), 0.73-0.68 (t).

Compound 75: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.62-8.58 (m), 8.57-8.53 (d), 7, 41-

7.39 (d), 7.38-7.35 (d), 7.27 (s), 7.23 (s), 7.13 (s), 6.61 (s), 6.51 (s), 5.60 -5.55 (t), 5.54-5.50 (t), 5.39-5.35 (d), 5.15 (s), 5.14-5.10 (m), 5. 09; s), 5.07 (s), 5.01 (s), 5.00 (s), 4.60-4.55 (br d), 4.51-4.49 (t), 4 , 40-4.38 (br d), 3.90 (s), 3.85 (s), 3.80 (s), 3.73 (s), 3.48-3.43 (br d) , 3.30-3.22 (dt), 2.95-2.88 (dt), 2.38-2.32 (br d), 2.27-2.22 (bd), 1.90- 1.70 (m), 1.69-1.62 (br d), 1.59-1.50 (m), 1.46-1.35 (m), 1.26 (s), 0.90- 0.85 (t), 0.82-0.78 (t).

Compound 76: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.95 (s), 8.80 (d), 8.55 (m), 8, 50 (m),

7.34 (s), 7.30 (s), 7.28 (s), 6.76 (s), 6.73 (s), 5.85 (q), 5.77 (q), 5.40 (m), 5.20-

5.35 (m), 4.60 (m), 4.35 (m), 3.98-3.85 (m), 3.80 (s), 3.48 (bt), 3.30-3, 18 (m), 3.00 (m). 2.40 (bd), 2.32 (bd), 2.26 (bd), 1.90-1.65 (m), 1.60 (s), 1.55 (dd), 1.48 ( d) 1.40 (m), 1.12 (m).

Compound 77 : ^! H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.53-8.43 (m), 7.56-7.20 (m), 7.04 ( s), 7.01 (s), 6.92-6.75 (m), 6.62 (br s), 5.85-5.78 (m), 5.77-5.68 (m) , 5.84-5.80 (br d), 5.12-5.02 (m), 4.00-3.76 (m), 3.76-3.64 (m), 3.60- 3.49 (m), 3.49-3.38 (m), 3.34-3.32 (d), 3.27-3.21 (m), 3.18-3.02 (m) , 2.82-2.73 (m), 2.53-2.37 m), 2.3271

2.24 (m), 2.20 (s), 2.15 (s), 1.72-1.27 (m), 1.22-1.07 (m), 0.97-0.92 (dd), 0.860.82 (dd).

Compound 78: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.65-8.56 (d), 8.55-8.51 (d), 7, 40-7.35 (d), 7.34-7.20 (m), 7.16 (s), 6.70-6.60 (m), 6.21-6.18 (d), 6 , 15-6.11 (d), 5.97-

5.88 (m), 5.83-5.75 (m), 5.45-5.40 (d), 5.32 (s), 5.28 (s), 5.27 (s), 5.21-5.18 (m), 5.13 (s), 5.11 (s), 4.67-4.61 (br d), 4.51-4.49 (d), 4. 35-4.33 (d), 4.05-4.00 (m), 3.95 (s), 3.94 (s), 3.90 (s), 3.84-3.82 (d) ), 3.81 (s), 3.66-3.60 (q), 3.50-3.45 (br d), 3.40 (s), 3.30 (s), 3.23- 3.17 (dt), 3.03-2.97 (br t), 2.86-2.80 (br t), 2.60-2.55 (br t), 2.50-2.40 (m), 2.30-2.25 (br d), 2.20 (s), 2.15-2.10 (br d), 1.90-1.65 (m),

1.64-1.60 (br d), 1.56-1.43 (m), 1.36-1.27 (m), 1.26-1.11 (m).

Compound 79: 1 H NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers):? 8.65-8.59 (d), 8.58-8.52 (d), 7.40-7.35 (d), 7.32-7.28 (d), 7.25-7.24 ( d), 7.13 (s). 6.65 (s), 6.60 (s), 6.20-6.18 (d), 6.12-

6.10 (d), 5.97-5.90 (m), 5.89-5.75 (m), 5.43-5.38 (d), 5.33-5.20 (m) , 5.16 (s), 5.15 (s), 5.10 (s), 4.60-4.58 (br d), 4.51-4.49 (d), 4.40-4 , 38 (d), 4.05-4.00 (m), 3.93-3.85 (m), 3.83 (s), 3.82 (s), 3.79 (s), 3 , 65-3.60 (q), 3.50-3.45 (br d), 3.39 (s), 3.30-3.18 (m), 2.95-2.80 (m) , 2.61-2.55 (m), 2.39-2.32 (br d), 2.20 (s), 1.90-

1.75 (m), 1.74-1.66 (m), 1.65-1.60 (m), 1.59-1.48 (m), 1.47-1.31 (m), 1 , 27-1.22 (m), 1.20-1.18 (d).

Compound 80; ^! H NMR spectrum (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.62-8.58 (d), 8.56-8.52 (d), 7.40-7, 35 (d), 7.30 (br s), 7.26 (s), 7.18 (s), 6.62 (s), 6.60 (s), 5.72-5.68 (t ), 5.62-5.58 (t),

5.40-5.36 (d), 5.30 (s), 5.18 (s), 5.17-5.13 (d), 5.10 (s), 4.66-4.61 (br d), 4.60-

4.58 (m), 4.31-4.29 (br d), 3.96 (s), 3.95 (s), 3.92 (s), 3.87 (s), 3.49 -3.43 (br d), 3.24-3.16 (dt), 3.04-2.96 (br t), 2.32-2.28 (br d), 2.17 (s) , 2.13-2.06 (m), 2.91-

2.85 (m), 2.81-1.64 (m), 1.63-1.55 (m), 1.54-1.40 (m), 1.36-1.00 (m), 0 , 93-0.87 (t), 0.83-0.77 (t).

Compound 81: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.62-8.58 (d), 8.56-8.52 (d), 7, 41-7.39 (d), 7.38-7.35 (d), 7.33-7.28 (d), 7.27 (s), 7.23 (s), 7.11 (s) ), 6.60 (s), 6.50 (s),

5.65-5.61 (t), 5.60-5.57 (t), 5.38-5.35 (dp 5.30 (s), 5.15 (s), 5.13-5 , 10 (d), 5.08 (s), 5.06 (s), 5.01 (s), 4.59-4.54 (br d), <40-4.38 (br d), 3.91 (s), 3.85 (s), 3.80 (s), 3.74 (s), 3.48-3.42 (br d), 3.30-3.23 qt), 2.95-2.90 (br t), 2.38-2.32 (br d),

2.18 (s), 1.90-1.75 (m), 1.74-1.46 (m), 1 / 4-1.10 (m), 0.94-0.88 (t) , 0.87-0.82 (t).

Compound 82: ¹ H NMR Spectrum Diastereoisomer, Mixture of Rotamers): I (d), 7.10 (d), 6.65 (s), 6.57 (s), 5.85 (q),: 5 , 04 (s), 4.60 (bd), 4.38 (d), 3.92 (s), 3.3 ·: 2.95 (dt), 2.40 (bd), 2.25 ( bd), 1.82 (m), 1.38 (m).

Compound 83: ¹ H NMR diastereomer, mixture of ^rotamers); 7.13 (dd), 7.08 (dd), 6.65 (s), 5.85 (q), 5. (bd), 4.34 (d), 3.95 (s), 3. 92 (s), 3.88 (s), (bd), 2.15 (bd). 1.80 (m), 1.70 (dt). 1.55

Compound 84: 1 H NMR spectrum of diastereoisomer, mixture of rotamers): 3 7.27 (d), 7.17 (s), 6.52 (AB-q), 5.81 (q), 5 4.58 -4.50 (m), 4.31 (m), 3.91 (s), 3.88 (s. (Ddd), 3.00 (ddd), 2.29 (br d), 2.12 (br c: 1.36 (d), 1.32 (d), 1.31 (d), 1.11 (m).

Compound 85: ¹ H NMR diastereomer, mixture of rotamers): m

7.25 (s), 7.13 (s), 6.58 (s), 5.80 (q), 5.76

4.50 (m), 4.31 (br d), 3.90 (s), 3.88 (s), 2.

(500 MHz, CDCl3), (single

7.35-7.28 (m), 7.26 (s), 7.24 (m), 7.14, 78 (q), 5.40 (d), 5.13 (s), 5. 07 (q) ,; (s), 3.80 (s), 3.48 (bd), 3.26 (dt).

, 64 (bd), 1.56 (s), 1.54 (d), 1.46 (d), juO MHz, CDCl ₃ ), (single

7.36 (s), 7.34 (m), 7.27 (m), 7.22 (d), (q), 5.40 (d), 5.10 (d), 5.04 ( s), 4.63

3.46 (bd), 3.22 (dt), 3.04 (dt), 2.33 d). 1.58-1.46 (m), 1.36 (d), 1.14 (m).

500 MHz, CDCl3), (single

8.53 (d), 8.52 (d), 7.42 (d), 7.31 (s),

1.74 (q), 5.10 (d), 5.04 (s), 5.03 (s),

3.87 (s), 3.85 (s), 3.41 (br d), 3.18, 1.78-1.72 (m), 1.68 (br d), 1.52 (d ),

500 MHz, CDCl3), (single

8.51 (d), 7.42 (d), 7.31 (s), 7.28 (d), (q), 5.33 (d), 5.10 (s), 5.02 ( s), 4.5681 (s), 3.79 (s), 3.46 (br d), 3.24 (ddd), 2.90 (ddd), 2.33 (br d), 2.21 (br d), 1.85-1.74 (m), 1.62 (m), 1.51 (d), 1.47 (d), 1.31 (d), 1.29 (d) .

Compound 86: 1 H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.61-8.45 (m), 7.38-7.28 (m), 6, 68 (s),

6.49 (s), 5.79 (q), 5.61 (q), 5.19-5.01 (m), 4.72-4.63 (m), 3.89-3.67 (m), 3,653.45 (m), 2.85 (t), 2.58 (t), 2.39-2.23 (m), 2.11-1.92 (m), 1.72 -1.45 (m), 1.39.16 (m), 0.89 (m).

Compound 87: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.60-8.48 (m), 7.38-7.15 (m), 6, 74-

6.63 (m), 6.62 (s), 6.52-6.47 (m), 5.75 (q), 5.61 (m), 5.32-5.25 (m), 5.15-5.01 (m), 4.72-4.59 (m), 3.93-3.80 (m), 3.75 (m), 3.62-3.43 (m) , 2.39-1.55 (m), 1.50 (dd), 1.36-1.21 (m).

Compound 88: H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): b 9.16 (d), 8.74 (d), 8.70 (d), 7.85 (cl),

I, JU il

(m),

5.38 (bd), 5.31 (bd), 5.24 (s),

5.20 (d), 4.60 (m), 4.34 (dd), 3.95-3.88 (m), 3.84 (s), 3.75 (s), 3.45 ( bd), 3.24 (dt), 3.19 (dt), 2.98 (bt), 2.34 (bd), 2.30 (bd), 2.22 (bd), 1.90-1 , 10 (m), 1.52 (d),

1.45 (d).

Compound 89: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): c 7.36-7.22 (m), 5.43 (d), 5.36 (quintet) ,

5.25 (quintet), 4.60-4.35 (t), 3.95 (s), 3.91 (s), 3.88 (s), 3.73 (d), 3.67 (d) , 3,47-

3.40 (br d), 3.24 (dt), 3.07 (dt), 2.38 (br d), 2.22 (br d), 1.85-1.60 (m), 1 , 58-

1.25 (m).

Compound 91: 1 H NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers): c 9.01-8.93 (m), 8.78 (m), 8.06 (m) ,

7.75 (s), 7.68 (t), 7.61 (t), 7.57 (d), 7.51-7.41 (t), 7.28-7.19 (t), 7.15 (t), 7.127.05 (t), 7.03 (s), 5.82 (q), 5.73 (t), 5.33 (d), 4.55 (d), 4 , 33 (d), 3.93-3.78 (m),

73.73 (s), 3.43 (br d), 3.21 (dt), 3.01 (t), 2.63 (t), 2.58 (t), 2.39 (br d) , 2.22 (d), 2.09-1.94 (m), 1.92-1.43 (m), 1.41-1.14 (m).

Compound 92: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.94 (d), 8.81 (m), 8.08 (m), 7.75 (s),

7.69 (t), 7.55 (d), 7.48 (t), 7.42 (m), 7.31 (s), 7.29-7.07 (m), 7.02 ( d) 5.81 (t),

5.71 (t), 5.40 (d), 4.56 (d), 4.34 (d), 3.92-3.79 (m), 3.40 (br d), 3.11 (dt), 2.96 (t), 2.61 (t), 2.50 (m), 2.22-1.91 (m), 1.90-1.35 (m), 1.20 (s), 1.02 (m), 0.83 (t).

Compound 93: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.62-8.55 (m), 7.66-7.58 (m), 7 , 57-

7.56 (m), 7.52-7.46 (m), 7.40-7.30 (m), 7.29-7.20 (m), 7.19-7.04 (m) , 6.96-6.79 (m), 6.77-6.69 (τη), 5.85-5.77 (m), 5.70-5.69 (ml, 5.43-5). 38 (m), 5.10-4.98 (m),

4th, 64-4.52 (m), 4.39-4.35 (m), 4.08-4.06 (m), 4.02-3.99 (m), 3.98-3 , 90 (m), 3,893.84 (m), 3,83-3,68 (m), 3,48-3,40 (m), 3,18 (ddd), 3,14 (ddd), 2 , 96 (ddd), 2.92 (dad), 2.68-2.58 (m), 2.57-2.51 (m). 2.37 (dd), 2.24-2.11 (m, 2.05-1.94 (m),

1.89-1.41 (m), 1.40-1.23 (m), 1.22-1.10 (m).

Compound 94: ¹ H NMR (500 MHz, CDCl ₃ ), (diastereoisomer mixture, rotamer mixture): δ 8.61-8.55 (m), 7.47-7.40 (m), 7.387 , 02 (t), 6.92-6.88 (t), 6.87-6.82 (t), 6.8 ^ -6.7 ¹ (t), 6.68-6.64 (t ), 5.77-5.72 (t), 5.65-5.59 (t), 5.40-5.36 (t), 5.11-5.04 (t), 5.02 ( s), 4.97 (s), 4.58-4.52 (τη), 4.36-4.33 (t), 3.87 (s), 3.83 (s), 3.77 ( s), 3.70 (s), 3.57-3.52 (m), 3.48-3.36 (m), 3.24 (ddd), 3.12 (ddd), 2.99 ( ddd), 2.81 (dad), 2.66-2.53 (m), 2.41-2.31 (m), 2.29-2.22 (m), 2.02-1.92 (m ), 1.88-1.45 (m), 1.44-1.21 (m).

Compound 95: 1 H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.91-8.75 (m), 7.38-7.29 (m), 7.287 , 02 (m), 6.92-6.88 (m), 6.92-6.80 (m), 6.79-6.76 (m), 6.74-6.71 (m), 6.69-6.64 (m), 6.09-5.98 (m), 5.78-5.70 (m), 5.65-5.60 (m), 5.40-5, 34 (m), 5.32-5.26 (m), 5.19-5.13 (m), 5.09-5.00 (m), 4.63-4.52 (m), 4 , 35-4.32 (m), 3.95-3.63 (m), 3.46 (br d)), 3.41 (br d), 3.24 (ddd), 3.12 (ddd) ), 3.02-2.92 (m), 2.67-2.45 (m), 2.41-

2.30 (τη), 2.27-2.21 (m), 2.20-2.12 (m), 2.01-1.90 (m), 1.89-1.04 (m) .

Compound 96: ¹ H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers); δ 8.59-8.54 (m), 7.67-7.57 (m), 7.55-

7.49 (m), 7.47-7.38 (m), 7.37-7.05 (m), 6.95-6.71 (m), 5.83 (t), 5.78 (t), 5.68 (t), 5.42-5.37 (m), 5.28 (s), 5.23-4.95 (m), 4.62-4.52 (m) , 4.38-4.32 (m), 3.93 (s),

3.92 (s), 3.88 (s), 3.87 (s), 3.47-3.38 (m), 3.18-3.07 (m), 2.98-2.87 (m) ), 2,67-

2.58 (m), 2.57-2.50 (m), 2.41-2.30 (m), 2.22-2.17 (m), 2.16-2.11 (m) , 2.03-1.92 (m), 1.89-1.21 (m), 1.20-1.09 (m).

Compound 97: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.62-8.52 (m), 7.64-7.54 (m), 7 , 52-

7.46 (m), 7.42-7.04 (m), 6.97-6.78 (m), 0.77-6.70 (m), 6.12-5.97 (m) , 5.85-5.76 (m), 5.69-5.61 (m), 5.46-5.35 (m), 5.33-5.24 (m), 5.10-5 , 01 (m), 4.70-4.52 (m), 4.39-4.33 (m), 3.92 (s), 3.91 (s), 3.88 (s), 3 , 87 (s), 3.48-3.41 (m), 3.18-3.10 (m), 2.97-2.90 (m), 2.67-2.57 (m), 2.56-2.50 (m), 2.42-2.31 (m), 2.23-2.10 (m), 2.04-

1.93 (m), 1.89-1.10 (m).

Compound 98: H NMR (500 MHz, CDCl ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.59-8.53 (m), 7.67-7.44 (m), 7.397, 03 (m), 6.94-6.78 (m), 6.77-6.66 (m), 6.46-6.33 (m), 6.03-5.93 (m), 5.83 (t), 5.78 (t), 5.68 (t), 5.64 (t), 5.42-5.37 (m), 5.08-4.97 (m), 4.92 -4.66 (m), 4.64-4.52 (m), 4.40-4.33 (m), 3.94 (s), 3.92 (s), 3.90 (s) , 3.88 (s), 3.87-3.84 (m), 3.48-3.40 (m), 3.20-3.08 (m), 2.98-2.88 (m) ), 2.64-2.57 (m), 2.56-2.50 (m), 2.41-2.31 (m), 2.23-2.17 (m), 2.16- 2.10 (m), 2.03-1.92 (m), 1.88-1.08 (m).

Compound 99: Ή NMR spectrum (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): δ 8.67-8.58 (m), 8.54-8.48 (m), 7.497, 03 (m), 6.95-6.87 (m), 6.86-6.82 (m), 6.72-6.68 (m), 5.78-5.68 (m), 5 , 63-5.57 (m), 5.40-5.31 (m), 5.14-4.93 (m), 4.59-4.51 (m), 4.35-4.30 (m), 3.90-3.78 (m), 3.73 (s). 3.71 (s), 3.45 (br d), 3.38 (br d), 3.22 (ddd), 3.11 (ddd), 2.99-2.91 (m),

2.67-2.48 (m), 2.42-2.39 (m), 2.26-2.18 (m), 2.17-2.11 (m), 2.05-1, 92 (m), 1.89-

1.18 (m), 1.09-0.98 (m).

Compound 100: ¹ H NMR (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.63-8.56 (m), 7.68-7.59 (m), 7 , 57-

7.40 (m), 7.39-7.20 (m), 7.19-7.04 (m), 7.03-6.98 (m), 6.97-6.81 (m) , 6.78-6.71 (m), 5.80 (s), 5.77 (s), 5.67 (t), 5.62 (t), 5.40-5.34 (m) , 5.27-4.94 (m), 4.62-4.52 (m), 4.38-4.32 (m), 3.94 (s), 3.92 (s), 3, 91 (s), 3.88 (s), 3.87 (s), 3.82 (s), 3.81 (s), 3.47-3.37 (m), 3.18-3, 05 (m), 3.00-2.90 (m), 2.68-2.50 (m), 2.43-2.29 (m), 2.22-2.09 (m), 2 , 07-1.95 (m), 1.90-1.63 (m), 1.62-1.20 (m), 1.14-1.02 (m).

Compound 101: Ή NMR spectrum (500 MHz, CDCI ₃ ), (mixture of diastereoisomers, mixture of rotamers): δ 8.64-8.58 (m), 7.43-7.30 (m), 7 , 29-

7.19 (m), 7.18-7.02 (m), 6.98-6.94 (m), 6.93-6.87 (m), 6.86-6.83 (m) , 6.77-6.73 (m), 5.73 (t), 5.71 (t). 5.62 (t), 5.60 (t), 5.41-5.32 (m), 5.10-5.05 (m), 4.58-4.52 (m), 4.35 -4.30 (m), 3.94 (s), 3.93 (s), 3.91 (s), 3.90 (s), 3.88 (s), 3.34 (s), 3.83 (s), 3.78 (s), 3.76 (s), 3.45 (br d), 3.38 (br d), 3.22 (ddd), 3.10 (ddd) , 3.06-2.92 (m), 2.67-2.53 (m), 2.523-2.43 (m), 2.42-2.29 (m), 2.28-2.11 (m), 2.04-1.94 (m),

1.88-1.20 (m), 1.08-0.98 (m).

Compound 102: Ή NMR (500 MHz, CDCP), (mixture of diastereoisomers, mixture of rotamers): δ 8.63-8.57 (m), 7.66-7.60 (m), 7.58 -

7.54 (m). 7.53-7.47 (m), 7. 41-7.31 (m), 7.27-7.20 (m). 7.19-7.03 (m), 6.92-6.70 (m), 5.80 (t), 5.77 (t), 5.57 (t), 5.61 (t), 5.40-5.36 (m), 5.09-5.02 (m), 4.70-4.52 (m), 4.37-4.33 (m), 3.92 (s' ), 3.91 (s), 3.89 (s). 3.88 (s), 3.87 (s), 3.86 (s), 3.85 (s), 3.82-3.77 (m), 3.48-3.40 (m), 3.18-3.09 (m), 2.98-2.88 (m), 2.66-2.42 (m),

2.40-2.10 (m), 2.04-1.94 (m), 1.89-1.62 (m), 1.61-1.18 (m), 1.14-1, 13 (m).

Compound 103: H NMR (500 MHz, CDCI ₃ ), (diastereoisomer mixture, rotamers mixture): δ 7.76-7.59 (m), 7.50-7.40 (m), 7, 38-

7.18 (m), 7.17-7.05 (m), 6.93-6.87 (m), 6.7 7-6.73 (m), 6.18-6.15 (m) ), 5.85 (t), 5.79 (t), 5.20 (t), 5.16 (t), 5.41-5.38 (m), 5.21-5.08 (m ), 4.60-4.52 (m), 4.37-4.32 (m), 3.92 (s), 3.91 (s), 3.88 (s), 3.87 (s) ), 3.47-3.37 (m), 3.17-3.03 (m), 2.97-2.91 (m), 2.64-2.58 (m), 2.57- 2.50 (m), 2.42-2.33 (m), 2.05-1.95 (m), 1.90-1.80 (m), 1.79-1.62 (m) , 1.61-1.31 (m), 1.13-1.08 (m).

Compound 104: ¹ H NMR (500 MHz, CDCl 3), (mixture of diastereoisomers, mixture of rotamers): δ 7.47-7.41 (m), 7.37-7.02 (m), 5, 78-

5.72 (m), 5.18 (t), 5.12 (t), 5.40-5.37 (m), 5.10 (s), 5.08 (s), 5.07 ( s), 5.05 (s),

4.59-4.51 (m), 4.37-4.31 (m), 3.87 (s), 3.85 (s), 3.77 (s), 3.73 (s), 3.45 (br d),

3.37 (br d), 3.24 (ddd), 3.10 (ddd), 3.02-2.94 (m), 2.65-2.59 (m), 2.583-2.53 ( m), 2.52-2.46 (m), 2.43-2.35 (m), 2.27-2.22 (m), 2.21-2.15 (m), 2.05 -1.94 (m), 1.89-

1.30 (m), 1.10-1.01 (m).

Compound 105: ¹ H NMR (500 MHz, CDCl 3), (mixture of diastereoisomers, mixture of rotamers): δ 8.39 (d), 7.64 (q), 7.52 (q), 7.43 ( m), 7.29-7.03 (m), 5.02-4.88 (m), 4.60 (q), 4.46 (q), 3.62 (m), 3.52- 3.38 (m), 2.68-

2.49 (m), 2.31-2.13 (m), 2.09-1.75 (m), 1.74-1.44 (m), 1.29-1.16 (m) .

Compound 106: ¹ H NMR (500 MHz, CDCl 3), (single diastereoisomer, mixture of rotamers):: 8.43-8.34 (m). 7.46 (ddt), 7.39 (ddt), (br d), 3.92 (s), 3.90 (s), 3.88 (s), 3.87 (s), 3.45 (br d), 3.23 (dt), 3.05 (dt),

2.64-2.02 (m), 2.29 (br d), 2.13 (br d), 1.82-1.48 (m).

Compound 107: Ή NMR (500 MHz, CDCl3), (single diastereoisomer, mixture of rotamers): 7.34-7.23 (m), 5.31 (quintet), 5.12 (quintet), 4.74 (dd), 4.69 (dd), 4.52 (dq), 4.41 (dq), 3.93 (s), 3.90 (s), 3.82 (s),

3.70 (m), 3.56-3.43 (m), 2.34-1.88 (m).

Compound 108: 1 H NMR (500 MHz, CDCl 3), (single diastereoisomer, mixture of rotamers): δ 8.50 -8.31 (gi), 7.62 (d), 7.57 (d),

7.46 (d), 7.44-7.31 (m), 7.30 (s), 7.19 (q), 7.10 (q), 5.00 (m), 4.80 ( m), 4.69 (m),

4.56 (m), 3.97-3.71 (m), 3.61-3.43 (m), 2.68-2.41 (m), 2.344-2.12 (m) , 2.08-1.84 (m), 1.83-1.72 (m), 1.71-1.42 (m). 1.29-1.13 (m).

Compound 109: ¹ H NMR (500 MHz, CDCl 3), (single diastereoisomer, mixture of rotamers): δ 8.48-8.32 (m), 7.53 (dd), 7.47 (m)

7.25-7.14 (m), 5.02-4.89 (m), 4.79 (m), 4.49 (m), 3.73-3.55 (m), 3.48 (quintet),

3.30 (quintet), 2.69-2.44 (m), 2.32-1.41 (m), 1.32-1.04 (m), 1.01 (m).

Compound 110: 1 H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): ΐ 8.63 -8.51 (m), 8.50-8.31 (m), 8, 06 (m), 7.93-7.85 (m), 7.84-7.76 (m), 7.69 (d), 7.51-7.40 (m), 7.23-7 , 11 (m), 7.09 (t), 5.32 (d), 5.20 (m), 5.08 (m), 4.95 (m). 4.61-4.52 (m), 3.80 (m), 3.61 (m),

3.39 (t), 3.21 (dt), 2.94 (dt), 2.4-24-24 (m), 2.40 (d), 2.31 (m), 2.22- 2.14 (m), 2.13-1.91 (m), 1.90-1.13 (m).

Compound 111: 1 H NMR Spectrum (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers ?: 8.46-8.36 (m), 7.61 (dd), 7.52 (dd), 7.50-7.40 (t), 7.22-7.15 (t), 6.8? (Dd) 5.83 (dd), 6.07 (s), 6.04 (dd) , 5.35 (d), 5.10-5.06 (m), 4.98-4.92 (m), 4.6 (br o) 4.34 (d), 3.4 (br d), 3.15 (dt), 2.98 (dt),

2.68-2.50 (m), 2.24 (br d), 1.8-1.46 (rr \ 1.37-1.24 (m).

Compound 112: ¹ H NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers):: 8.7 (d), 8.6 (d), 7.7-7.6 (dd) , 7.45 (s),

7.3-7.2 (m), 6.9 (d), 6.1 (d), 5.3 (m), 4.5 (d), 4.4 (d), 3.45 ( dd), 3.4-3.3 (m), 3.12 (m), 2.85-2.8 (m), 2.4 (dd), 1.97-1.7 (m), 1, 6-1.35 (m).

Compound 113: ¹ H NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers): ό 8.7 (d), 8.6 (d), 8.5 (m), 7.7- 7.6 (dd),

7.3 (s), 7.2 (m), 5.4 (d), 5.3 (m), 4.6 (br d), 4.4 (br d), 3.95 (s) , 3.90 (s), 3.85 (s), 3.45 (dd), 3.3-3.2 (dd), 3.1-2.9 (m), 2.4 (dd) , 1.95 (s), 1.9-1.7 (m), 1.6-1.35 (m).

Compound 114: Ή NMR (500 MHz, CDCl 3), (single diastereoisomer, mixture of rotamers): δ 8.49 (d), 7.52 (q), 7.31 (s), 7.18 (s ), 7.12-6.99 (m), 5.31 (d). 4.99 (m), 4.54 d), 3.92-3.79 (m), 3.42 (br d), 3.22 (dt), 3.02 (dt), 2.81- 2.62 (m), 2.60 (t), 2.30 or d), 2.13 (d), 1.82-1.19 (m).

Compound 115: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.63 -8.53 (m), 7.43-7.37 (d), 7.357, 23 (m), 7.17 (s), 6.56 (s), 6.54 (s), 5.48-5.42 (d), 5.41-5.38 (d), 5. 32-5.29 (d), 5.20-5.10 (m), 4.68-4.62 (br d), 4.32-4.30 (d), 4.00-3.90 (m), 3.86 (s), 3.53-3.47 (br d), 3.25-3.20 (dt), 3.05-3.00 (dt), 2.37-2 , 21 (br d), 2.10-2.00 (m), 1.92-1.87 (m), 1.80-1.70 (m), 1.69-1.59 (m) , 1.57-1.43 (m), 1.34-1.15 (m), 0.97-0.92 (d), 0.85-0.78 (d), 0.77-0 , 75 (d), 0.66-0.64 (d).

Compound 116: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): δ 8.65 -8.55 (m), 7.42-7.40 (d), 7. 39-

7.37 (d), 7.33-7.30 (d), 7.26 (s), 7.22 (s), 7.10 (s), 6.60 (s), 6.42 ( s), 5.42-5.40 (d), 5.39-5.37 (d), 5.34-5.32 (d), 5.16 (s), 5.15-5.11 (m), 5.10 (s), 5.07-4.94 (q),

4.60-4.55 (br d), 4.41-4.39 (br d), 3.93 (s), 3.84 (s), 3.80 (s), 3.70 (s) ), 3.48-3.43 (br d), 3.30-3.22 (dt), 2.96-2.90 (dt), 2.39-2.35 (br d). 2.29-2.25 (br d), 2.052.00 (m), 1.90-1.75 (m), 1.65-1.60 (m), 1.59-1.48 (m ), 1.47-1.33 (m), 0.95-0.87 (d), 0.86-0.83 (d), 0.82-0.78 (d), 0.73- 0.69 (a).

Compound 117: 1 H NMR (500 MHz, CDCl ₃ ), (single diastereoisomer, mixture of rotamers): c 8.65 -8.60 (d), 8.59-8.52 (d), 7 , 45-

7.39 (d), 7.38-7.23 (m), 7.21 (s), 6.67 (s), 6.66 (s), 5.83-5.79 (t), 5. 78-5.75 (t), 5.74-5.63 (m), 5.53-5.48 (m), 5.45-5.41 (br d), 5.20-5.05 (m), 5.04 (s), 5.01 (s), 4.99 (s), 4.72-4.68 (br d), 4.35-4.32 (br d), 3 , 98 (s), 3.97 (s), 3.93 (s), 3.90 (s),

3.85 (s), 3.55-3.48 (br d), 3.32-3.24 (dt), 3.10-3.03 (dt), 2.70-2.62 (m ), 2,61-

2.56 (m), 2.55-2.45 (m), 2.39-2.32 (br d), 2.20-2.15 (br d), 1.97-1.70 ( m), 1.69-

1.60 (m), 1.59-1.47 (m), 1.40-1.20 (m), 0.93-0.90 (m).

Compound 118: ¹ H NMR (500 MHz, CDCI ₃ ), (single diastereoisomer, mixture of rotamers): c 8.66 -8.62 (d), 8.61-8.59 (d), 7.467, 44 (d), 7.43-7.40 (d), 7.39-7.33 (d), 7.31 (s), 7.28 (s), 7.16 (s), 6. 68 (s), 6.57 (s), 5.80-5.75 (t), 5.74-5.67 (m), 5.43-5.40 (d), 5.20-5 , 05 (m), 4.64-4.60 (br d), 4.43-4.41 (br d), 3.96 (s), 3.90 (s), 3.85 (s) , 3.78 (s), 3.53-3.49 (br d), 3.35-3.28 (dt), 3.02-2.96 (br t), 2.70-2.50 (m), 2.42-2.36 (br d), 2.32-2.29 (br d), 1.91-1.78 (m), 1.73-1.68 (br d) , 1.63-1.55 (m), 1.50-1.40 (m).

Example 13 - MDR-SENSITIZATION TESTS

Cell lines known to be resistant to a drug may be used to test the ability of the compounds of the present invention to increase the antiproliferative activity of drugs. These cell lines include (but are not limited to) cell lines L1210, P388D, CHO and MCF7. Alternatively, such resistant cell lines may be created. The cell line is exposed to the drug to which it is resistant or to the action of a test substance; the cell vitality is then measured and compared with that of the drug that is exposed to the drug in the presence of the test substance.

We performed tests using leukemia cells from L1210 mice with the pHaMDR1 / A retrovirus carrying MDR1 cDNA, as described by Pastan et al., Proc. Natl. Acad. Sci., Vol. 85, 4486-4490 (1988). Resistant cells, designated L1210VMDRC.06, were obtained from Dr. Μ. M. Gottesman from the National Cancer Institute. These drug-resistant transfectants were selected by culturing the cells in 0.06 mg / ml colchicine.

Multi-drug resistance assays were performed by placing the cells in 96-well microtiter containers (2.10 ³ , 1.10 ⁴ or 5.10 ⁵ cells / well) and subjecting them to doxorubicin at a concentration range of 50 nM to 10 pM, in the presence of or the absence of the multidrug resistance modifier compounds of the present invention (1, 2.5, or 10 pM, as described by Ford et al., Cancer Res., Vol. 50, 1748-1 756 (1990). After 3 days of cultivation , cell viability was quantified using MTT (Mos sman) or XTT dyes for evaluation of mitochondrial function All definitions were repeated 4 to 8 times See also Mossman, T., J. Immunol Methods, Vol 65, 55-63 (1983).

The results were determined by comparing IC50 for doxorubicin without additives with IC ₅₀ for doxorubicin + MDR inhibitor. The MDR ratio (IC ₅₀ Dox / IC ₅₀ Dox + Inhibitor) was calculated and the resulting value (integer) was used to compare the effectiveness of the compounds.

In all tests, the compounds of the present invention were tested for their inherent antiproliferative or cytotoxic activity. The results are summarized in Table 2 below. As shown in Table 2, the compounds generally cause <10% cytotoxicity at concentrations of 10 pM or greater.

The compounds of formula (I) have also been tested for MDRsensitizing activity with other MDR cell lines including several human cell lines (e.g., myeloma cells (8226 / DOX6, 8226 / DOX40, MDR10V. MR 20), melanoma cells ( VCR 4.5, VBL 3.0, COL-1), GM3639 T-cells, breast carcinoma MCF-7, bronchogenic adenocarcinoma A549, LOX melanoma, P388 / ADR P338 and VMDRC.04, as well as various chemotherapeutic drugs (eg doxorubicin, vincristine, vinblastine) , taxol, colchicine and etoposide) These tests yielded results similar to those shown in Table 2 (data not shown Thus, the efficacy of the compounds of the present invention to sensitize multidrug resistance was further demonstrated, although we have described a number of ingredients of the present invention it should be clear that our principles can be modified to include other ingredients using products, processes or methods of the present invention. Therefore, it should be understood that the scope of the present invention is defined by the appended claims, and not by its specific constituents exemplified.

Table 2: Estimated compounds relative to ± 1a_reversing_of multidrug resistance

Comp. IC50D0X self IC50DOX + 1 μΜ IC ₅₀ Dox + 2.5 μΜ 2 900PM 400 4 800 400 6 900 300 8 800 500 10 6500 625 11 700 200 12 6500 350 15 800 400 21 1000 700 27 1200 900 31 1300 900 43 6500 600 44 400 200 47 900 800 48 1400 800 49 5000 700 52 900 500 S3 1600 700 54 6500 510 55 900 400 56 400 300 64 1500 700 66 1600 1300 69 800 400 84 6000 350 98 6000 2000 105 9000 2800 Sat. 1800 80 FK506 400 400

IC ₅₀ Dox + 10 μΜ MDRotn. 1 μΜ MDR-1 Rel. 2.5 μΜ MDRotn. 10 μΜ <60 2.25 > 15 <60 2 2.7 <60 3 > 15 100 1.6 10.4 8 <60 3.5 18.6 > 12 <60 2 > 13 90 1.4 11.1 200 1.3 6 500 1.4 10.8 2.6 <60 2 > 6 100 1.1 9 100 1.75 7.1 14 <60 1.8 > 15 200 2.3 12.7 8 <60 2.25 > 15 <60 1.3 > 7 400 2.1 3.75 400 1.3 4 <60 2 17.1 3 > 13 500 3.2 22.5 16 100 1 4

Claims (17)

Patent Claims 1. Compounds of general formula (I): where A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl); where B and D are independently of one another and denote: hydrogen, Ar, (C 1 -C 10) straight or branched chain alkyl groups, (C 2 -C 10) straight or branched chain alkynyl or alkynyl groups; substituted with (C5-C7) -cycloalkyl groups: (C1-C5) straight or branched chain alkyl groups, (C2-C6) straight or branched chain alkynyl or alkynyl groups; substituted with (C5-C7) -cycloalkenyl groups: (C1-C6) straight- or branched-chain alkyl groups, (C2-C6) straight- or branched-chain alkynyl or alkynyl groups; or straight- or branched-chain (C 1 -C 6) alkyl groups. Straight or branched (C2-C6) alkenyl or alkynyl groups; in any case, any of the CH ₂ groups of said alkyl, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of O, S, SO, SO ₂ , N and NR, where R is selected from the group consisting of hydrogen, a straight or branched (C1-C4) alkyl group, a straight or branched (C2-C4) alkenyl or alkynyl group, and (C1-C4) alkyl alkyl a group wherein the bridge is formed between the nitrogen and carbon atoms of said heteroatom-containing chain so as to form a ring; the ring in question may be fused to an Ar group; or: the group wherein Q is hydrogen, straight or branched (C 1 -C 6) -alkyl or straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; wherein T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxyl, O- (C 1 -C 4) - alkyl of or O- (C2-C4) -alkenyl groups; provided that at least one of B or D is selected from the group consisting of a straight or branched (C2-C10) -alkynyl group substituted by a (C5C7) -cycloalkyl radical of a (C2-C6) -alkynyl group having a straight or branched chain a chain substituted by a (C5-C7) -cycloalkenyl radical (C2-C6) -a / straight or branched quinyl group and an Ar-substituted (C2-C6) straight or branched chain alkynyl group; wherein Ar is a carbocyclic aromatic moiety selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl and anthracenyl; or: heterocyclic aromatic rings selected from the group consisting of 2 furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolinyl, 2-pyrazolinyl, 2-pyrazolinyl, 2-pyrazolinyl , isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3 triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithanyl, indolizinyl , indolylo, isoindolyl, 3H-indolyl, indolinyl, benzo [b] furanyl, benzo [b] thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cynolinyl triazinyl, quinazolinyl, quinoxalinyl, 1,8naftiridinil, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl; wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6) straight or branched chain alkyl, (C 2 -C6)> straight or branched chain alkenyl groups, 0- (C1-C4) straight or branched chain alkyl groups, 0- (C2-C4) straight or branched chain alkenyl groups, 0-benzyl, 0- phenyl, 1,2-methylenedioxy, amino, carboxyl, straight- or branched-chain straight or branched N- (C 1 -C 5 -alkyl or alkenyl) carboxamide, straight or branched (C 1 -C 5 -alkyl) single chain or straight or branched C2-C5-alkenyl) -carboxamides, N-morpholino-carboxamide, Ν-benzylcarboxamide, N-thiomorpholino-carboxamide, N-picolinoyl where X is 4-methoxyphenyl, 2-pyridyl, 2-pyridyl -pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, q being 0-2; where L is hydrogen or U; M is oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U; where U is hydrogen, straight or branched 0- (C 1 -C 4) -alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups; Straight or branched (C2-C6) alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y; wherein Y is a carbocyclic aromatic moiety selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl and anthracenyl; or heterocyclic aromatic groups as defined above; wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups (C1-C6) - straight or branched chain alkenyl groups, 0- (C1-C4) straight or branched chain alkyl groups; O- (C2-C4) straight or branched chain alkenyl groups, O-benzyl, O-phenyl, 1,2methylenedioxy, amino and carboxyl; wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or wherein J and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO ₂ ; and where m is 0-3. Compounds according to claim 1 of formula I wherein A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl); where B and D are independently of one another and denote Ar, (C 1 -C 10) -alkyl, alkenyl or alkynyl straight or branched chain groups; substituted with (C5-C7) -cycloalkyl groups (C1-C6) -alkyl, alkenyl or alkynyl straight or branched chain groups; substituted by (C5-C7) -cycloalkenyl groups (C6B) -alkyl, alkenyl or alkynyl straight or branched chain groups; or straight or branched (C 1 -C 6) -alkyl, alkenyl or alkynyl groups; in any case, any of the CH ₂ groups of said alkyd, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of 0, S, SO and SO ₂ ; or the group wherein O is hydrogen, straight or branched (C 1 -C 6) -alkyl or straight or branched (C 2 -C 6) -alkenyl groups; wherein T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxyl, O- (C 1 -C 4) - alkyl or O- (C2-C4) -alkenyl groups; provided that at least one of B or D is selected from the group consisting of a straight or branched (C2-C10) -alkynyl group substituted by a (C5C7) -cycloalkyl radical of a (C2-C6) -alkynyl group having a straight or branched chain a chain substituted with a (C5-C7) -cycloalkenyl moiety (C2-C6) -alkynyl group with a straight or branched chain and an Ar-substituted (C2-C6) -alkynyl group with a straight or branched chain; wherein Ar is selected from the group consisting of phenyl, 1-naphthyl, 2naphthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienide, 2-pyridyl, 3-pyridyl, 4-pyridyl, and mono- and bicyclic heterocyclic ring systems having the size of the individual rings of 5 or 6 atoms and containing in one or both rings a total of 1-4 heteroatoms selected independently from oxygen, nitrogen and sulfur; wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6) straight or branched chain alkyl, (C 2 -C 6 -alkenyl straight or branched chain groups, O- (C 1 -C 4) straight or branched chain alkyl groups, O- (C 2 -C 4) straight or branched chain alkenyl groups, O-benzyl, O- phenyl, 1,2-methylenedioxy, amino, carboxyl, straight- or branched-chain straight or branched N- (C 1 -C 5 -alkyl or alkenyl) -carboxamides, N, N -di- (C 1 -C 5 -alkyl or alkenyl with straight or branched chain) or branched chain) carboxamides, N-morpholino-carboxamide, N-benzylcarboxamide, Νthiomorpholino-carboxamide, N-picolinoyl-carboxamide, 0-X, CH ₂ - (CH ₂ ) _q X, 0- (CH ₂ ) _q - X , (CH ₂ ) _q - Ο - X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, with q being 0- 2; where L is oxygen or U; M is hydrogen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U; wherein U is hydrogen, O- (C1-C4) straight or branched chain alkyl groups or O- (C1-C4) straight or branched chain alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups or straight or branched (C 1 -C 6) alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y; wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2naphthyl, 2-furyl, 3-furyl, 2-thienyl. 3-thienyl, 2-pyridyl, 3-pyridyl, 4pyridyl, as well as mono- and bicyclic heterocyclic ring systems with ring sizes of 5 or 6 atoms and containing in one or both rings a total of 1-4 heteroatoms selected independently from oxygen , nitrogen and sulfur; wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups (C1-C6) straight- or branched-chain alkenyl groups; straight- or branched-chain O- (C 1 -C 4) alkyl groups; O- (C2-C4) straight- or branched-chain alkenyl groups, O-benzyl, O-phenyl, 1,2methylenedioxy, amino and carboxyl; wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or where .1 and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S , SO and SO ₂ ; and where m is 0-3. Compounds according to claim 1 of formula (I): where A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl); where B and D are independently: denote Ar, straight or branched (C 1 -C 10) -alkyl groups, straight or branched (C 2 -C 10) alkenyl or alkynyl groups; substituted by (C5-C7) -cycloalkyl groups: (C1-C6) straight- or branched-chain alkyl groups, (C2-C6) -alkenyl or straight- or branched-chain alkynyl groups; substituted by (C5-C7) cycloalkenyl groups: (C1-C6) straight or branched chain alkyl groups, (C2-C6) straight or branched chain alkynyl or alkynyl groups; or straight or branched (C 1 -C 6) -alkyl, straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; in any case, any of the CH ₂ groups of said alkyl, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of O, S, SO, SO ₂ , N and NR, where R is selected from the group consisting of hydrogen, a (C 1 -C 4) straight or branched chain alkyl group, a (C 2 -C 4) alkenyl or straight or branched chain alkynyl group, and a (C 1 -C 4) bridged alkyl group, wherein the bridge is formed between the nitrogen and carbon atoms of said heteroatom-containing chain so as to form a ring; the ring in question may be fused to an Ar group; or: the group wherein Q is hydrogen, straight or branched (C 1 -C 6) -alkyl, straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; where T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxyl, O- (C 1 -C 4) -alkyl or O- (C2-C4) -alkenyl groups; provided that at least one of B or D is selected independently from a group consisting of Ar ', Ar'-substituted (C 1 -C 6) -alkyl straight or branched chain groups and Ar'-substituted (C 2 -C 6) - straight or branched alkenyl or alkynyl groups; wherein Ar 'is an Ar-group substituted by one to three substituents independently selected from the group consisting of N- (C 1 -C 5 -alkyl or C 2 -C 5 -alkenyl of straight or branched chain) -carboxamides, Ν, Ν -di- (C1-C5alkyl or straight or branched C2-C5-alkenyl) -carboxamides, Nmorpholino-carboxamide, N-benzylcarboxamide, N-thiomorpholinocarboxamide, N-picolinoylcarboxamide, O-CH, _q -CH - _{q 2} - CH ₂ - CH ₂ - X, O (CH ₂ ) _q - X, (CH ₂ ) _q - Ο - X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazoyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, where q is 0- 2; wherein Ar is a carbocyclic aromatic moiety selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl and anthracenyl; or a heterocyclic aromatic residue selected from the group consisting of 2furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl. 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxazole yl, 1,2,3-triazolyl, 1,3,4- thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3Hindolyl, indolinyl, benzo [b] furanyl, benzo [b] thiophenyl, 1H-benzoyl, 1H-benzoyl, 1H-benzoyl, 1H-thiazolidinyl; benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8naphthyridinyl, pteridinyl, carbaz olyl, acridinyl, phenazinyl, phenothiaz phenyl and phenoxazinyl; wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6) straight or branched chain alkyl, (C 2 -C6) straight or branched chain alkenyl groups, O- (C1-C4) straight or branched chain alkyl groups, O- (C2-C4) straight or branched chain alkenyl groups, O-benzyl, O- phenyl, 1,2-methylenedioxy, amino, carboxyl. N- (C192 Straight or branched C5-alkyl or alkenyl) -carboxamides, Ν, straight- or branched-chain (C1-C5-straight or branched alkyl or straight or branched C2-C5-alkenyl) -carboxamides, N-morpholino-carboxamide, Νbenzylcarboxamide, N-thiomorpholino-carboxamide, N-picolinoylcarboxamide, O-X, CH ₂ - (CH ₂ ) _q - X, 0- (CH,) _q - X, (CH ₂ ) _q - Ο - X and CH = CH -X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, lyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, with q being 0- 2; where L is hydrogen or U; M is oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U; wherein U is hydrogen, straight- or branched-chain O- (C 1 -C 4) -alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups; Straight or branched (C2-C6) alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y; wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, as well as heterocyclic aromatic residues as defined above; wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups, (C1-1- Straight or branched C6-alkenyl groups, straight or branched C- (C1-C4) alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups, O-benzyl, O-phenyl, 1,2-methylenedioxy, amino and carboxyl; wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or wherein J and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO ₂ ; and where m is 0-3. Pharmaceutical compositions for the treatment or prophylaxis of multidrug resistance, comprising a pharmaceutically effective amount of a compound according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier, excipient or motor. Pharmaceutical compositions according to claim 4, further comprising a chemotherapeutic agent. Pharmaceutical compositions according to claims 4 or 5, further comprising a chemosensitizer other than the compounds according to any one of claims 1 to 3. 7. Methods for the treatment or prophylaxis of multidrug resistance in patients comprising the step of administering to said patients pharmaceutical compositions comprising a pharmaceutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier, excipient or motor, the compound having the formula ( I): (I) wherein A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl); where B and D are independently of one another: denote hydrogen, Ar, (C 1 -C 10) straight or branched chain alkyl groups, (C 2 -C 10) straight or branched chain alkynyl or alkynyl groups; substituted by (C5-C7) -cycloalkyl groups: (C1-C6) straight- or branched-chain alkyl groups, (C2-C6) -alkenyl or straight- or branched-chain alkynyl groups; substituted by (C5-C7) cycloalkenyl groups: (C1-C6) straight or branched chain alkyl groups, (C2-C6) straight or branched chain alkynyl or alkynyl groups; or straight or branched (C 1 -C 6) -alkyl or straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; in any case, any of the CH ₂ groups of said alkyl, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of O, S, SO, SO ₂ , N and NR, where R is selected from the group consisting of hydrogen, a (C 1 -C 4) straight or branched chain alkyl group, a (C 2 -C 4) alkenyl or straight or branched chain alkynyl group, and a (C 1 -C 4) bridged alkyl group, wherein the bridge is formed between the nitrogen and carbon atoms of said heteroatom-containing chain so as to form a ring; the fingers in question may be condensed with an Ar group; or: the group wherein Q is hydrogen, straight or branched (C 1 -C 6) -alkyl or straight or branched (C 2 -C 6) -alkenyl or alkynyl groups; wherein T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxide, O- (C 1 -C 4) -alkyl or O- (C2-C4) -alkenyl groups; wherein Ar is a carbocyclic aromatic moiety selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl and anthracenyl; or: heterocyclic aromatic rings selected from the group consisting of 2 furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolinyl, 2-pyrazolinyl, 2-pyrazolinyl , isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3 triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5 triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl , isoindolyl, 3Hindolyl, indolinyl, benzo [b] furanyl, benzo [b] thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, pta inyl, quinazolinyl, quinoxalinyl, 1,8 naphthyridinyl, pteridinium, carbazolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl; wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups, ( C2-C6) straight or branched chain alkenyl groups, 0- (C1-C4) straight or branched chain alkyl groups, 0- (C2-C4) straight or branched chain alkenyl groups, 0-benzyl, 0 -phenyl, 1,2-methylenedioxy, amino, carboxyl, straight- or branched-chain straight or branched N- (C 1 -C 5 -alkyl or alkenyl) -carboxamides, Ν, Ν or - (C 1 -C 5 -alkyl with straight or branched chain) unsaturated alkyl or C2-C5 alkenyl straight or branched alkenyl) carboxamides, N-morpholino-carboxamide Νbenzilkarboksamid, N-thiomorpholino-carboxamide, N-picolinoylcarboxamide, 0-X, CH ₂ - (CH _{2) q} - X, O- (CIS-X, (CH ₂ ) _q - O - X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5- dimethylisoxazoyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2 thienyl, 3-thienyl and pyrimidyl, with q being 0-2; where L is hydrogen or U; M is oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U; wherein U is hydrogen, straight- or branched-chain O- (C 1 -C 4) -alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups; Straight or branched (C2-C6) alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y; wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolyl, 2-imidazolinyl, imidazolidinyl, 2H -pyranyl, 4H-pyranyl, piperidyl, 1,4-dioxanyl, morpholinyl, 1,4dithianyl, thiomorpholinyl, piperazinyl, quinuclidinyl and heterocyclic aromatic groups, as defined above; wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups (C1-C6) straight- or branched-chain alkenyl groups; straight- or branched-chain O- (C 1 -C 4) alkyl groups; O- (C2-C4) straight or branched chain alkenyl groups, Obenzyl, O-phenyl, 1,2-methylenedioxy, amino and carboxyl; wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or wherein J and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO ₂ ; and where m is 0-3. Methods for the treatment or prophylaxis of multidrug resistance in patients, comprising the step of administering to the patients in question a pharmaceutical, a composition comprising a pharmaceutically effective amount of a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant or motor, with the adjuvant formula (I): (I) wherein A is CH ₂ , oxygen, NH or N- (C 1 -C 4 -alkyl); where 8 and D are independently: denote Ar, straight or branched (C 1 -C 10) -alkyl groups, straight or branched (C 2 -C 10) alkenyl or alkynyl groups; substituted with (C5-C7) -cycloalkyl groups (C1-C6) -alkyl, alkenyl or alkynyl straight or branched chain groups; substituted by (C5-C7) cycloalkenyl groups (C1-C6) -alkyl, alkenyl or alkynyl groups, straight or branched; or straight or branched (C 1 -C 6) -alkyl, alkenyl or alkynyl groups; in any case, any of the CH ₂ groups of said alkyl, alkenyl or alkynyl chains may optionally be replaced by a heteroatom selected from the group consisting of O, S, SO and SO ₂ ; or the group Q wherein Q is hydrogen, straight or branched (C 1 -C 6) -alkyl or straight or branched (C 1 -C 6) -alkenyl groups; where T is Ar or a substituted 5- to 7-membered cycloalkyl group with substituents at positions 3 and 4 which are independently selected from the group consisting of oxo, hydrogen, hydroxyl, O- (C 1 -C 4) -alkyl or O- (C2-C4) -alkenyl groups; wherein Ac is selected from the group consisting of phenyl, 1-naphthyl, 2naphthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and mono- and bicyclic heterocyclic ring systems having the size of the individual rings of 5 or 6 atoms and containing in one or both rings a total of 1-4 heteroatoms selected independently from oxygen, nitrogen and sulfur; wherein Ar may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6) straight or branched chain alkyl, (C 2 -C6) straight or branched chain alkenyl groups, O- (C1-C4) straight or branched chain alkyl groups, O- (C2-C4) straight or branched chain alkenyl groups, O-benzyl, O- phenyl, 1,2-methylenedioxy, amino, carboxyl, straight- or branched-chain straight or branched N- (C 1 -C 5 -alkyl or alkenyl) -carboxamides, straight or branched C 1 -C 5 -alkyl Onnen alkyl or C2-C5 alkenyl straight or branched alkenyl) carboxamides, N-morpholino-carboxamide Νbenzilkarboksamid, N-thiomorpholino-carboxamide, N-picolinoylcarboxamide, O-X, CH ₂ - (CH _{2) q} - X, O- (CH ₂ ) _q - X, (CH ₂ ) _q - Ο - X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, where q is 0- 2; where L is hydrogen or U; M is oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen, then L is U; wherein U is hydrogen, straight- or branched-chain O- (C 1 -C 4) -alkyl groups; Straight- or branched-chain O- (C2-C4) -alkenyl groups; Straight or branched (C 1 -C 6) -alkyl groups; (C1-C6) straight or branched chain alkenyl groups; (C5-C7) -cycloalkyl or (C5-C7) -cycloalkenyl groups substituted with straight or branched (C1-C4) alkyl groups or straight or branched (C2-C4) -alkenyl groups; [(C1-C4) -alkyl or (C2-C4) -alkenyl] -Y or Y; wherein Y is selected from the group consisting of phenyl, 1-naphthyl, 2naphthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and mono- and bicyclic heterocyclic ring systems having the size of the individual rings of 5 or 6 atoms and containing in one or both rings a total of 1-4 heteroatoms selected independently from oxygen, nitrogen and sulfur; wherein Y may contain one to three substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6) straight- or branched-chain alkyl groups (C1-C6) straight- or branched-chain alkenyl groups; straight- or branched-chain O- (C 1 -C 4) alkyl groups; O- (C2-C4) straight- or branched-chain alkenyl groups, O-benzyl, O-phenyl, 1,2methylenedioxy, amino and carboxyl; wherein J is hydrogen, (C 1 -C 2) -alkyl or benzyl; K is a (C1-C4) straight- or branched-chain alkyl group, benzyl or cyclohexylmethyl, or wherein J and K may together form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO ₂ ; and where m is 0-3. The method of claim 7 or claim 8, wherein in formula (I) at least one of B or D is independently selected from the group consisting of: (C 2 -C 10) straight or branched chain alkynyl groups; substituted by (C5C7) -cycloalkyl groups (C2-C6) - straight or branched alkynyl groups 100 chains; substituted by (C5-C7) -cycloalkenyl groups (C2-C6) - straight or branched alkynyl groups; or Ar-substituted (C2-C6) straight or branched chain alkynyl groups. The method of claim 7 or claim 8, wherein in formula (I) at least one of B or D is independently selected from the group consisting of: Ar *; Ar'-substituted (C1-C6) - straight- or branched-chain alkyl groups; Ar'-substituted (C2-C6) - straight or branched alkenyl or alkynyl groups; wherein Ar 'is an Ar-residue containing one to three substituents independently selected from the group consisting of: N- (C 1 -C 5 -alkyl or straight or branched chain alkenyl) -carboxamides, N, N -di- (C 1 C5-straight or branched alkyl or C2-C5 alkenyl straight or branched alkenyl) carboxamides, N-morpholino-carboxamide, N-benzylcarboxamide, Ntiomorfolino-carboxamide, N-picolinoyl-carboxamide, O-X, CH ₂ - (CH ₂ ) _q X, 0- (CH ₂ ) _q - X, (CH ₂ ) _q - Ο - X and CH = CH-X; wherein X is 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl and pyrimidyl, with q being 0- 2; The method of any one of claims 7 to 11, wherein in formula (I), J and K together form a 5-7 membered ring. The method of any one of claims 7 to 11, wherein in formula (I) at least one of the substituents B and D is independently represented by the formula (CH ₂ ) _r - (X) - (CH ₂ ) _S - Ar, wherein : r is 0-4; s is 0-1; Ar is defined as in claim 1; and each X is independently selected from the group consisting of: CH ₂ , O, S, 101 SO, N and NR, wherein R is selected from the group consisting of: hydrogen, straight or branched (C 1 -C 4) alkyl; Straight or branched (C2-C4) -alkenyl or alkynyl; (C1-C4) -bosyl alkyl, forming a bridge between the nitrogen atom and the Ar-group. The method of claim 7, wherein said compounds of formula (I) are selected from the group consisting of: (S) -1- (2-oxo- 4-pyridin-3-yl-1- (3-pyridin-3-yl) propyl) butyl ester 2- (3,4,5-trimethoxyphenyl) acetyl) piperidine-2-carboxylic acid; (R) -1- (2-oxo- 4-pyridin-3-yl-1- (3-pyridin-3-yl) propyl) butyl ester 2- (3,4,5-trimethoxyphenyl) acetyl) piperidine-2-carboxylic acid; pharmaceutically acceptable derivatives thereof and mixtures thereof. The method of any of claims 7 to 13, wherein the compounds are administered orally. The method of any one of claims 7 to 14, wherein the compounds are not substantially immunosuppressive at the dosage required to achieve chemosensitization. The use of the compounds according to any one of claims 1 to 3 for multidrug resistance therapy or prophylaxis, 17. Methods for the Preparation of Compounds of Formula (D):